2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/2iy5wruuedsh6.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/00yc7rcvua6a7.js","/_next/static/immutable/chunks/37ktb71aq3480.js","/_next/static/immutable/chunks/2d50b-7eu4558.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/2d6noqpp6ehas.js","/_next/static/immutable/chunks/1sx186c93bpzg.js","/_next/static/immutable/chunks/3dc-1n866s65i.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2w1bvggzb0ga8.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T76d,This case describes a 29-year-old man with Morbihan disease, characterized by a 5-year history of recurrent facial erythema, papules, and pustules, followed by persistent right face edema. Initially misdiagnosed as lupus erythematosus, he received multiple treatments with only transient relief. Clinical manifestations combined with pathological findings confirmed a diagnosis of Morbihan disease associated with rosacea. Notably, the patient developed erythema and papules on the inner thighs, along with small papules on the trunk and upper limbs for 3 months. A biopsy revealed nonspecific inflammation. Since the morphology of these lesions differed from any known skin disease and no other cause could be identified, we believe this may be a manifestation of the disease. Extra-facial manifestation not previously reported. Various therapies were attempted: doxycycline and azelaic acid improved erythema; baricitinib was ineffective; while omalizumab and intense pulsed light (IPL) achieved partial improvement in erythema and edema. Long-term isotretinoin therapy provided sustained remission without relapse during tapering, confirming its efficacy and safety. This case expands the clinical spectrum of Morbihan disease by documenting extra-facial involvement and reported isotretinoin as an effective long-term therapy, with omalizumab and IPL as promising adjuncts. Furthermore, the literature review (2004-2025) summarizes the clinical features, pathology, and treatment responses of reported cases, showing a male-to-female ratio of 2.81:1. Lymphatic or vascular dilation was significantly correlated with a favorable outcome. Conversely, dermal edema and granuloma were inversely associated with treatment efficacy, indicating poorer prognosis. However, based on uncontrolled data, these findings are strictly hypothesis-generating and do not establish a definitive treatment hierarchy.31:T619,Of 653 participants enrolled, 323 were randomized in MVOR-1 (247 [76.5%] women; mean [SD] age, 47.2 [13.7] years) and 330 were randomized in MVOR-2 (249 [75.5%] women; mean [SD] age, 51.6 [14.0] years). DFD-29 demonstrated superior efficacy in IGA success rates compared with placebo (MVOR-1: treatment difference [TD], 32.9%; 95% CI, 19.6-46.2; P < .001; MVOR-2: TD, 34.1%; 95% CI, 21.3-46.8; P < .001) and compared with doxycycline (MVOR-1: TD, 18.0%; 95% CI, 5.0-31.1; P = .01; MVOR-2: TD, 28.3%; 95% CI, 17.4-39.3; P < .001). DFD-29 also showed superior efficacy in least-squares mean reductions in total inflammatory lesions vs placebo (MVOR-1: TD, -9.2; 95% CI, -11.5 to -6.9; P < .001; MVOR-2: TD, -6.8; 95% CI, -8.9 to -4.8; P < .001) and doxycycline (MVOR-1: TD, -4.7; 95% CI, -6.7 to -2.8; P < .001; MVOR-2: TD, -3.5; 95% CI, -5.4 to -1.6; P < .001). Adverse events with DFD-29, doxycycline, and placebo were reported in 32 of 121 (26.4%), 25 of 116 (21.6%), and 27 of 76 (35.5%), respectively, in MVOR-1 and 51 of 122 (41.8%), 40 of 121 (33.1%), and 30 of 82 (36.6%), respectively, in MVOR-2. The most common adverse events with DFD-29, doxycycline, and placebo were nasopharyngitis, reported in 4 of 121 (3.3%), 2 of 116 (1.7%), and 3 of 76 (3.9%), respectively, in MVOR-1 and 13 of 122 (10.7%), 10 of 121 (8.3%), and 13 of 82 (15.9%), respectively, in MVOR-2, and COVID-19, reported in 4 of 121 (3.3%), 3 of 116 (2.6%), and 4 of 76 (5.3%) in MVOR-1 and 7 of 122 (5.7%), 8 of 121 (6.6%), and 5 of 82 (6.1%) in MVOR-2.32:Tb0f,A low-dose modified formulation of minocycline hydrochloride, DFD-29, is under evaluation for treating papulopustular rosacea (PPR). To determine the efficacy and safety of DFD-29, 40 mg, compared with doxycycline, 40 mg, and placebo for treating PPR. This study included data from 2 double-blind, placebo-controlled, phase 3 randomized clinical trials (MVOR-1 and MVOR-2) conducted between March 2022 and May 2023 at 61 centers in the US and Germany. Healthy adults 18 years and older with moderate to severe PPR were included. Participants were randomized 3:3:2 to oral DFD-29 (minocycline hydrochloride capsules), 40 mg; doxycycline, 40 mg; or placebo once daily for 16 weeks. The coprimary efficacy outcomes were (1) proportion of participants with Investigator's Global Assessment (IGA) treatment success with DFD-29 vs placebo and (2) total inflammatory lesion count reductions with DFD-29 vs placebo. Secondary outcomes included comparisons between DFD-29 and doxycycline in coprimary outcomes and between DFD-29 and placebo in erythema reduction. Of 653 participants enrolled, 323 were randomized in MVOR-1 (247 [76.5%] women; mean [SD] age, 47.2 [13.7] years) and 330 were randomized in MVOR-2 (249 [75.5%] women; mean [SD] age, 51.6 [14.0] years). DFD-29 demonstrated superior efficacy in IGA success rates compared with placebo (MVOR-1: treatment difference [TD], 32.9%; 95% CI, 19.6-46.2; P < .001; MVOR-2: TD, 34.1%; 95% CI, 21.3-46.8; P < .001) and compared with doxycycline (MVOR-1: TD, 18.0%; 95% CI, 5.0-31.1; P = .01; MVOR-2: TD, 28.3%; 95% CI, 17.4-39.3; P < .001). DFD-29 also showed superior efficacy in least-squares mean reductions in total inflammatory lesions vs placebo (MVOR-1: TD, -9.2; 95% CI, -11.5 to -6.9; P < .001; MVOR-2: TD, -6.8; 95% CI, -8.9 to -4.8; P < .001) and doxycycline (MVOR-1: TD, -4.7; 95% CI, -6.7 to -2.8; P < .001; MVOR-2: TD, -3.5; 95% CI, -5.4 to -1.6; P < .001). Adverse events with DFD-29, doxycycline, and placebo were reported in 32 of 121 (26.4%), 25 of 116 (21.6%), and 27 of 76 (35.5%), respectively, in MVOR-1 and 51 of 122 (41.8%), 40 of 121 (33.1%), and 30 of 82 (36.6%), respectively, in MVOR-2. The most common adverse events with DFD-29, doxycycline, and placebo were nasopharyngitis, reported in 4 of 121 (3.3%), 2 of 116 (1.7%), and 3 of 76 (3.9%), respectively, in MVOR-1 and 13 of 122 (10.7%), 10 of 121 (8.3%), and 13 of 82 (15.9%), respectively, in MVOR-2, and COVID-19, reported in 4 of 121 (3.3%), 3 of 116 (2.6%), and 4 of 76 (5.3%) in MVOR-1 and 7 of 122 (5.7%), 8 of 121 (6.6%), and 5 of 82 (6.1%) in MVOR-2. In this study, DFD-29 was superior in efficacy to both doxycycline and placebo and demonstrated a favorable risk-benefit profile in the treatment of PPR. ClinicalTrials.gov Identifiers: NCT05296629 and NCT05343455.33:Tffd,IntroductionA low-dose modified formulation of minocycline hydrochloride, DFD-29, is under evaluation for treating papulopustular rosacea (PPR).ObjectiveTo determine the efficacy and safety of DFD-29, 40 mg, compared with doxycycline, 40 mg, and placebo for treating PPR.Design, Setting, and ParticipantsThis study included data from 2 double-blind, placebo-controlled, phase 3 randomized clinical trials (MVOR-1 and MVOR-2) conducted between March 2022 and May 2023 at 61 centers in the US and Germany. Healthy adults 18 years and older with moderate to severe PPR were included.InterventionsParticipants were randomized 3:3:2 to oral DFD-29 (minocycline hydrochloride capsules), 40 mg; doxycycline, 40 mg; or placebo once daily for 16 weeks.Main Outcomes and MeasuresThe coprimary efficacy outcomes were (1) proportion of participants with Investigator’s Global Assessment (IGA) treatment success with DFD-29 vs placebo and (2) total inflammatory lesion count reductions with DFD-29 vs placebo. Secondary outcomes included comparisons between DFD-29 and doxycycline in coprimary outcomes and between DFD-29 and placebo in erythema reduction.ResultsOf 653 participants enrolled, 323 were randomized in MVOR-1 (247 [76.5%] women; mean [SD] age, 47.2 [13.7] years) and 330 were randomized in MVOR-2 (249 [75.5%] women; mean [SD] age, 51.6 [14.0] years). DFD-29 demonstrated superior efficacy in IGA success rates compared with placebo (MVOR-1: treatment difference [TD], 32.9%; 95% CI, 19.6-46.2; P &lt; .001; MVOR-2: TD, 34.1%; 95% CI, 21.3-46.8; P &lt; .001) and compared with doxycycline (MVOR-1: TD, 18.0%; 95% CI, 5.0-31.1; P = .01; MVOR-2: TD, 28.3%; 95% CI, 17.4-39.3; P &lt; .001). DFD-29 also showed superior efficacy in least-squares mean reductions in total inflammatory lesions vs placebo (MVOR-1: TD, −9.2; 95% CI, −11.5 to −6.9; P &lt; .001; MVOR-2: TD, −6.8; 95% CI, −8.9 to −4.8; P &lt; .001) and doxycycline (MVOR-1: TD, −4.7; 95% CI, −6.7 to −2.8; P &lt; .001; MVOR-2: TD, −3.5; 95% CI, −5.4 to −1.6; P &lt; .001). Adverse events with DFD-29, doxycycline, and placebo were reported in 32 of 121 (26.4%), 25 of 116 (21.6%), and 27 of 76 (35.5%), respectively, in MVOR-1 and 51 of 122 (41.8%), 40 of 121 (33.1%), and 30 of 82 (36.6%), respectively, in MVOR-2. The most common adverse events with DFD-29, doxycycline, and placebo were nasopharyngitis, reported in 4 of 121 (3.3%), 2 of 116 (1.7%), and 3 of 76 (3.9%), respectively, in MVOR-1 and 13 of 122 (10.7%), 10 of 121 (8.3%), and 13 of 82 (15.9%), respectively, in MVOR-2, and COVID-19, reported in 4 of 121 (3.3%), 3 of 116 (2.6%), and 4 of 76 (5.3%) in MVOR-1 and 7 of 122 (5.7%), 8 of 121 (6.6%), and 5 of 82 (6.1%) in MVOR-2.Conclusions and RelevanceIn this study, DFD-29 was superior in efficacy to both doxycycline and placebo and demonstrated a favorable risk-benefit profile in the treatment of PPR.Trial RegistrationClinicalTrials.gov Identifiers: NCT05296629 and NCT0534345534:T593,Acne vulgaris commonly affects adults, adolescents, and preadolescents aged 9 years or older. The objective of this study was to provide evidence-based recommendations for the management of acne. A work group conducted a systematic review and applied the Grading of Recommendations, Assessment, Development, and Evaluation approach for assessing the certainty of evidence and formulating and grading recommendations. This guideline presents 18 evidence-based recommendations and 5 good practice statements. Strong recommendations are made for benzoyl peroxide, topical retinoids, topical antibiotics, and oral doxycycline. Oral isotretinoin is strongly recommended for acne that is severe, causing psychosocial burden or scarring, or failing standard oral or topical therapy. Conditional recommendations are made for topical clascoterone, salicylic acid, and azelaic acid, as well as for oral minocycline, sarecycline, combined oral contraceptive pills, and spironolactone. Combining topical therapies with multiple mechanisms of action, limiting systemic antibiotic use, combining systemic antibiotics with topical therapies, and adding intralesional corticosteroid injections for larger acne lesions are recommended as good practice statements. Analysis is based on the best available evidence at the time of the systematic review. These guidelines provide evidence-based recommendations for the management of acne vulgaris.25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"doxycycline: generic Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on doxycycline (generic). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/generic/doxycycline\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Generics\",\"item\":\"https://www.reachrx.ai/hub/tag/generic\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"doxycycline\",\"item\":\"https://www.reachrx.ai/hub/tag/generic/doxycycline\"}]}}"}}]],["$","$L2f",null,{"title":"doxycycline: Research & Clinical Takeaways","description":"Explore research on doxycycline (generic) — efficacy, safety, and comparative data.","papers":[{"doi":"10.2340/actadv.v106.adv-2026-0686","pmid":"42704880","title":"A Long Way to Diagnosis: Linear IgA Dermatosis Mimicking Prurigo Pigmentosa","journal_title":"Acta Dermato-Venereologica","journal_issn":"1651-2057","published_at":"2026-09-07T00:00:00.000Z","url":"https://doi.org/10.2340/actadv.v106.adv-2026-0686","source_score":1,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-09-16T06:23:04.041Z","updated_at":"2026-09-16T06:23:04.041Z","tags":[{"paper_doi":"10.2340/actadv.v106.adv-2026-0686","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0686","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0686","tag_type":"condition","value":"Linear IgA Dermatosis","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0686","tag_type":"condition","value":"Prurigo Pigmentosa","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0686","tag_type":"generic","value":"clobetasol","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0686","tag_type":"generic","value":"dapsone","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0686","tag_type":"generic","value":"doxycycline","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0686","tag_type":"generic","value":"minocycline","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0686","tag_type":"generic","value":"prednisolone","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0686","tag_type":"impact_flag","value":"safety_signal","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0686","tag_type":"level_of_evidence","value":"5","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0686","tag_type":"modality","value":"Phototherapy","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0686","tag_type":"modality","value":"Sulfone Antibiotic","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0686","tag_type":"modality","value":"Tetracycline Antibiotic","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0686","tag_type":"sample_size","value":"n=1","value_numeric":1},{"paper_doi":"10.2340/actadv.v106.adv-2026-0686","tag_type":"sex","value":"male","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0686","tag_type":"study_design","value":"Case Report","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0686","tag_type":"warning","value":"Concomitant IgG autoantibodies against BP180 C-terminal fragment were detected alongside IgA — this dual response (~20–25% of LAD cases per cited literature) may complicate diagnosis if only IgG-based assays are used.","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0686","tag_type":"warning","value":"The 'safety signal' impact flag reflects the clinically significant rebound flare after unsupervised dapsone discontinuation, which has clear patient safety implications.","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0686","tag_type":"warning","value":"This is a single case report (n=1); findings cannot be generalized to broader LAD populations.","value_numeric":null}],"summaries":{"what_studied":"A case report of a 51-year-old Caucasian man with a 15-month diagnostic odyssey, initially presenting with severely pruritic skin lesions clinically and histologically consistent with prurigo pigmentosa (PP), who was ultimately diagnosed with linear IgA dermatosis (LAD) after repeated biopsies and immunofluorescence studies.","key_result":"LAD was confirmed only after 5 perilesional biopsies — when direct IF finally showed linear IgA deposits along the dermal-epidermal junction, coinciding with the first appearance of tense blisters (~15 months after initial presentation). IgA reactivity against LAD-1 (120 kDa ectodomain of BP180) and concomitant IgG autoantibodies against the C-terminal fragment of BP180 were identified. Dapsone achieved marked and sustained remission.","limitations":"Single case report with no generalizability; repeated direct and indirect IF were negative for over a year, raising questions about optimal biopsy timing and technique; the 15-month delay may partly reflect disease biology rather than diagnostic error alone.","practice_takeaway":"In patients with recurrent neutrophil-rich dermatitis and persistent pruritus, do not exclude LAD on the basis of negative immunofluorescence — repeat perilesional biopsies are warranted, especially during active flares with new blisters. Dapsone is effective for LAD even when initial IF is negative, and discontinuation can trigger severe rebound."}},{"doi":"10.1111/acem.70400","pmid":"42690545","title":"Informed Consent for Pediatric Lyme Meningitis Study: In‐Person Versus Remote Approach","journal_title":"Academic Emergency Medicine","journal_issn":"1069-6563","published_at":"2026-09-03T00:00:00.000Z","url":"https://doi.org/10.1111/acem.70400","source_score":1,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-09-10T06:20:08.446Z","updated_at":"2026-09-10T06:20:08.446Z","tags":[{"paper_doi":"10.1111/acem.70400","tag_type":"age_group","value":"pediatric","value_numeric":null},{"paper_doi":"10.1111/acem.70400","tag_type":"category","value":"Emergency Medicine","value_numeric":null},{"paper_doi":"10.1111/acem.70400","tag_type":"condition","value":"Lyme Meningitis","value_numeric":null},{"paper_doi":"10.1111/acem.70400","tag_type":"generic","value":"ceftriaxone","value_numeric":null},{"paper_doi":"10.1111/acem.70400","tag_type":"generic","value":"doxycycline","value_numeric":null},{"paper_doi":"10.1111/acem.70400","tag_type":"impact_flag","value":"confirms_prior","value_numeric":null},{"paper_doi":"10.1111/acem.70400","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1111/acem.70400","tag_type":"modality","value":"Antibiotic","value_numeric":null},{"paper_doi":"10.1111/acem.70400","tag_type":"sample_size","value":"n=302","value_numeric":302},{"paper_doi":"10.1111/acem.70400","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1111/acem.70400","tag_type":"study_design","value":"Prospective Observational Study","value_numeric":null},{"paper_doi":"10.1111/acem.70400","tag_type":"warning","value":"Sample size tag reflects the number of patients approached for consent (302), not the total eligible pool (360) or enrolled participants (253) — clinicians should note this distinction.","value_numeric":null},{"paper_doi":"10.1111/acem.70400","tag_type":"warning","value":"The minimal-risk IRB designation limits generalizability to studies requiring written documentation of informed consent.","value_numeric":null},{"paper_doi":"10.1111/acem.70400","tag_type":"warning","value":"The study's primary focus is research methodology (consent process), not clinical treatment outcomes; the antibiotic comparison (ceftriaxone vs. doxycycline) is the parent study, not the subject of this paper.","value_numeric":null}],"summaries":{"what_studied":"This 21-center prospective observational study compared remote (telephone-based) versus in-person informed consent approaches for enrolling children aged 1–21 years with Lyme meningitis, evaluating whether consent location affected enrollment rates.","key_result":"Of 302 approached, 253 (83.8%) enrolled. Remote consent achieved 84.4% (196/232) enrollment versus 81.4% (57/70) in-person — a difference of 3.1% (95% CI −6.0% to 14.5%), indicating no statistically significant difference between approaches.","limitations":"- Underpowered to detect small differences in consent rates.\n- Site and staff characteristics that may affect enrollment were not captured.\n- Findings may not generalize to studies requiring written consent documentation (i.e., greater than minimal-risk studies).","practice_takeaway":"Remote telephone-based consent is as effective as in-person consent for enrolling children in minimal-risk clinical studies, especially when eligibility confirmation is delayed after the initial encounter. Advance notification during the clinical visit — combined with flexible, staged consent — supports enrollment rates above 80% across diverse centers."}},{"doi":"10.1093/humrep/deag133","pmid":"42618515","title":"A double-blind multi-centre randomised placebo-controlled trial of doxycycline in women with recurrent miscarriage and chronic endometritis defined by CD138 positive stromal cells","journal_title":"Human Reproduction","journal_issn":"0268-1161","published_at":"2026-08-20T00:00:00.000Z","url":"https://doi.org/10.1093/humrep/deag133","source_score":7,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-09-04T06:22:18.679Z","updated_at":"2026-09-04T06:22:18.679Z","tags":[{"paper_doi":"10.1093/humrep/deag133","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1093/humrep/deag133","tag_type":"category","value":"Obstetrics & Gynecology","value_numeric":null},{"paper_doi":"10.1093/humrep/deag133","tag_type":"condition","value":"Chronic Endometritis","value_numeric":null},{"paper_doi":"10.1093/humrep/deag133","tag_type":"condition","value":"Recurrent Miscarriage","value_numeric":null},{"paper_doi":"10.1093/humrep/deag133","tag_type":"generic","value":"doxycycline","value_numeric":null},{"paper_doi":"10.1093/humrep/deag133","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1093/humrep/deag133","tag_type":"level_of_evidence","value":"1","value_numeric":null},{"paper_doi":"10.1093/humrep/deag133","tag_type":"modality","value":"Antibiotic","value_numeric":null},{"paper_doi":"10.1093/humrep/deag133","tag_type":"sample_size","value":"n=438","value_numeric":438},{"paper_doi":"10.1093/humrep/deag133","tag_type":"sex","value":"female","value_numeric":null},{"paper_doi":"10.1093/humrep/deag133","tag_type":"study_design","value":"Randomized Controlled Trial","value_numeric":null},{"paper_doi":"10.1093/humrep/deag133","tag_type":"warning","value":"The CD138 definition used here (all CD138+ stromal cells, not only morphological plasma cells) is broader than in many prior studies, which may affect generalizability to trials using stricter diagnostic criteria.","value_numeric":null},{"paper_doi":"10.1093/humrep/deag133","tag_type":"warning","value":"The trial was stopped early at interim analysis per its adaptive Bayesian design; while results were consistent across sensitivity analyses, early stopping could theoretically underestimate variance.","value_numeric":null},{"paper_doi":"10.1093/humrep/deag133","tag_type":"warning","value":"The unexpected finding that CD138-negative women had lower livebirth rates than the CD138-positive placebo group is counterintuitive and may reflect selection or screening bias rather than a causal relationship.","value_numeric":null}],"summaries":{"what_studied":"This adaptive, double-blind, placebo-controlled RCT evaluated whether 14 days of preconceptual doxycycline 100 mg twice daily (vs. placebo) improved livebirth rates in 438 women aged 18–<42 with ≥2 consecutive first-trimester miscarriages and CD138+ chronic endometritis, across 27 UK sites (January 2020–October 2023).","key_result":"Cumulative livebirth or ongoing pregnancy rates were nearly identical: 52% (113/219) with doxycycline vs. 50% (109/219) with placebo (aRR 1.02; 95% CrI 0.85–1.21). Notably, CD138-negative women had *lower* livebirth rates than the placebo-treated CD138-positive group (30% vs. 41%, aRR 0.73; CrI 0.56–0.95), and CD138 expression did not change after doxycycline vs. placebo, suggesting inter-cycle variation rather than true chronic endometritis.","limitations":"- The CD138 diagnostic threshold was broad (all CD138+ stromal cells, not only morphological plasma cells), potentially inflating CE prevalence and diluting any true treatment effect.\n- Repeat biopsies were taken within the same treatment cycle, so a post-menstruation change in CD138 expression cannot be excluded.\n- Trial was stopped early at interim analysis per adaptive Bayesian design, though results were consistent across sensitivity analyses.","practice_takeaway":"Doxycycline should not be routinely offered to women with recurrent miscarriage on the basis of CD138+ chronic endometritis alone — it does not improve livebirth rates over placebo. Guidelines recommending antibiotic treatment for CD138-defined CE in this population should be reconsidered."}},{"doi":"10.1093/ofid/ofag484","pmid":"42582731","title":"Impact of Changes in Chlamydia Treatment Guidelines on Recurrent/Persistent Rectal\n Chlamydia trachomatis\n Infections","journal_title":"Open Forum Infectious Diseases","journal_issn":"2328-8957","published_at":"2026-08-11T00:00:00.000Z","url":"https://doi.org/10.1093/ofid/ofag484","source_score":17,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-08-19T06:28:55.618Z","updated_at":"2026-08-19T06:28:55.618Z","tags":[{"paper_doi":"10.1093/ofid/ofag484","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1093/ofid/ofag484","tag_type":"category","value":"Infectious Diseases","value_numeric":null},{"paper_doi":"10.1093/ofid/ofag484","tag_type":"condition","value":"Rectal Chlamydia Trachomatis Infection","value_numeric":null},{"paper_doi":"10.1093/ofid/ofag484","tag_type":"condition","value":"Rectal Gonorrhea","value_numeric":null},{"paper_doi":"10.1093/ofid/ofag484","tag_type":"generic","value":"azithromycin","value_numeric":null},{"paper_doi":"10.1093/ofid/ofag484","tag_type":"generic","value":"doxycycline","value_numeric":null},{"paper_doi":"10.1093/ofid/ofag484","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1093/ofid/ofag484","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1093/ofid/ofag484","tag_type":"modality","value":"Antibiotic","value_numeric":null},{"paper_doi":"10.1093/ofid/ofag484","tag_type":"sample_size","value":"n=433","value_numeric":433},{"paper_doi":"10.1093/ofid/ofag484","tag_type":"sex","value":"male","value_numeric":null},{"paper_doi":"10.1093/ofid/ofag484","tag_type":"study_design","value":"Controlled Interrupted Time Series","value_numeric":null},{"paper_doi":"10.1093/ofid/ofag484","tag_type":"warning","value":"Sample size (n=433) reflects total RP infections (211 RP-CT + 222 RP-GC), not the full clinic population; the broader analytic population for correlates analysis is not separately reported with a total N.","value_numeric":null},{"paper_doi":"10.1093/ofid/ofag484","tag_type":"warning","value":"Study population is exclusively MSM at a single urban sexual health clinic; findings may not apply to women, heterosexual men, or other clinical settings.","value_numeric":null},{"paper_doi":"10.1093/ofid/ofag484","tag_type":"warning","value":"The controlled ITS design cannot fully exclude confounding by concurrent changes such as COVID-19, mpox outbreaks, or doxy-PEP rollout, though these were partially addressed with a control outcome and sensitivity analyses.","value_numeric":null}],"summaries":{"what_studied":"This controlled interrupted time series (cITS) analysis evaluated whether switching from azithromycin to exclusive doxycycline for rectal *Chlamydia trachomatis* (CT) at a Seattle sexual health clinic (mid-2016 clinic change; July 2021 national CDC update) reduced recurrent/persistent rectal CT (RP-CT) among MSM from January 2012 through December 2024, using recurrent/persistent rectal gonorrhea (RP-GC) as a control outcome.","key_result":"In the fully implemented period (post-October 2021), the quarterly trend in RP-CT decreased significantly by **16.9% more** than the RP-GC trend compared to preimplementation (rate ratio 0.831; 95% CI: 0.719–0.957; P=.011). The RP-CT trend alone fell 14.7% from preimplementation to the fully implemented period (rate ratio 0.853; 95% CI: 0.765–0.951; P=.004). A total of 211 RP-CT and 222 RP-GC cases were identified across the study period.","limitations":"- EHR-based case ascertainment depended on voluntary return for re-testing (estimated at only 10–20.5% of MSM), likely missing most RP infections and creating selection bias.\n- Single-clinic setting limits generalizability.\n- The effect of doxycycline post-exposure prophylaxis (doxy-PEP) rollout (∼50% uptake by 2024) could not be fully separated from the guideline-change effect on RP-CT.","practice_takeaway":"Switching rectal CT treatment protocols to exclusive doxycycline—ahead of the 2021 CDC guideline update—was associated with a sustained, significant decline in recurrent/persistent rectal CT among MSM; clinics still prescribing azithromycin for rectal CT should align with current guidelines. Providers should also be aware that White patients and those with HIV were more likely to receive azithromycin after guidelines changed, suggesting residual prescriber bias worth monitoring."}},{"doi":"10.1093/cid/ciag470","pmid":"42548283","title":"Development and Application of an Anaerobic Activity Index","journal_title":"Clinical Infectious Diseases","journal_issn":"1058-4838","published_at":"2026-08-04T00:00:00.000Z","url":"https://doi.org/10.1093/cid/ciag470","source_score":6,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-08-09T13:25:10.186Z","updated_at":"2026-08-09T13:25:10.186Z","tags":[{"paper_doi":"10.1093/cid/ciag470","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1093/cid/ciag470","tag_type":"category","value":"Infectious Diseases","value_numeric":null},{"paper_doi":"10.1093/cid/ciag470","tag_type":"condition","value":"Burn Injury","value_numeric":null},{"paper_doi":"10.1093/cid/ciag470","tag_type":"condition","value":"Healthcare-Associated Infection","value_numeric":null},{"paper_doi":"10.1093/cid/ciag470","tag_type":"generic","value":"aztreonam","value_numeric":null},{"paper_doi":"10.1093/cid/ciag470","tag_type":"generic","value":"doxycycline","value_numeric":null},{"paper_doi":"10.1093/cid/ciag470","tag_type":"generic","value":"ertapenem","value_numeric":null},{"paper_doi":"10.1093/cid/ciag470","tag_type":"generic","value":"meropenem","value_numeric":null},{"paper_doi":"10.1093/cid/ciag470","tag_type":"generic","value":"penicillin","value_numeric":null},{"paper_doi":"10.1093/cid/ciag470","tag_type":"generic","value":"tigecycline","value_numeric":null},{"paper_doi":"10.1093/cid/ciag470","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1093/cid/ciag470","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1093/cid/ciag470","tag_type":"modality","value":"Antibiotic Stewardship","value_numeric":null},{"paper_doi":"10.1093/cid/ciag470","tag_type":"modality","value":"Carbapenem","value_numeric":null},{"paper_doi":"10.1093/cid/ciag470","tag_type":"modality","value":"Glycylcycline","value_numeric":null},{"paper_doi":"10.1093/cid/ciag470","tag_type":"study_design","value":"Cohort Study with Index Development","value_numeric":null},{"paper_doi":"10.1093/cid/ciag470","tag_type":"warning","value":"Age group was inferred as 'adult' based on burn patient context; the paper does not explicitly state the age distribution of the cohort.","value_numeric":null},{"paper_doi":"10.1093/cid/ciag470","tag_type":"warning","value":"Sample size for the burn cohort was not reported in the abstract or results excerpt; no sample_size tag could be assigned.","value_numeric":null},{"paper_doi":"10.1093/cid/ciag470","tag_type":"warning","value":"The impact_flag 'practice_changing' is applied cautiously — authors explicitly position the AAI as a research tool, but the novel scoring framework and outcome association may influence antibiotic stewardship practices.","value_numeric":null},{"paper_doi":"10.1093/cid/ciag470","tag_type":"warning","value":"The study design combines index development (using literature data from 88 papers) with retrospective cohort validation in burn patients — these are two distinct methodologies; the level of evidence tag reflects the cohort validation component.","value_numeric":null}],"summaries":{"what_studied":"This study developed an Anaerobic Activity Index (AAI) — a numeric score quantifying anti-anaerobic antibiotic exposure — for 21 antibiotics using in vitro susceptibility data across 7 anaerobic bacterial groups, then validated it in a burn patient cohort by examining the association between 7-day AAI quartiles and a 90-day composite outcome (culture positivity with bacteria of interest, healthcare-associated infection, and/or death).","key_result":"AAI scores ranged from 4 (aztreonam) to 59 (meropenem); in burn patients, the highest AAI quartile was associated with nearly 3× greater odds of the composite 90-day outcome vs. the lowest quartile (OR 2.90; 95% CI 1.65–5.08), after adjusting for Baux score and Charlson comorbidity index.","limitations":"- Validation was limited to a single, specialized population (burn patients), restricting generalizability.\n- Several antibiotics could not be scored due to insufficient in vitro susceptibility data.\n- The AAI is acknowledged to require future updating as new susceptibility data emerge.","practice_takeaway":"Clinicians should be aware that broad anti-anaerobic agents (e.g., meropenem, ertapenem, tigecycline) carry the highest AAI scores and, in burn patients, high cumulative anaerobic exposure was linked to worse outcomes. Until further prospective data are available, the AAI is best used as a research tool rather than a clinical decision rule."}},{"doi":"10.1503/cmaj.260142","pmid":"42442795","title":"Tick-borne anaplasmosis and myocarditis in eastern Ontario","journal_title":"Canadian Medical Association Journal","journal_issn":"0820-3946","published_at":"2026-07-12T00:00:00.000Z","url":"https://doi.org/10.1503/cmaj.260142","source_score":206,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-07-16T13:37:22.736Z","updated_at":"2026-07-16T13:37:22.736Z","tags":[{"paper_doi":"10.1503/cmaj.260142","tag_type":"age_group","value":"older_adult","value_numeric":null},{"paper_doi":"10.1503/cmaj.260142","tag_type":"category","value":"Medicine, General & Internal","value_numeric":null},{"paper_doi":"10.1503/cmaj.260142","tag_type":"condition","value":"Anaplasmosis","value_numeric":null},{"paper_doi":"10.1503/cmaj.260142","tag_type":"condition","value":"Myocarditis","value_numeric":null},{"paper_doi":"10.1503/cmaj.260142","tag_type":"condition","value":"Tick-Borne Disease","value_numeric":null},{"paper_doi":"10.1503/cmaj.260142","tag_type":"generic","value":"doxycycline","value_numeric":null},{"paper_doi":"10.1503/cmaj.260142","tag_type":"impact_flag","value":"safety_signal","value_numeric":null},{"paper_doi":"10.1503/cmaj.260142","tag_type":"level_of_evidence","value":"5","value_numeric":null},{"paper_doi":"10.1503/cmaj.260142","tag_type":"modality","value":"Antibiotic","value_numeric":null},{"paper_doi":"10.1503/cmaj.260142","tag_type":"sample_size","value":"n=1","value_numeric":1},{"paper_doi":"10.1503/cmaj.260142","tag_type":"sex","value":"male","value_numeric":null},{"paper_doi":"10.1503/cmaj.260142","tag_type":"study_design","value":"Case Report","value_numeric":null},{"paper_doi":"10.1503/cmaj.260142","tag_type":"warning","value":"Anaplasmosis incidence figure cited (40 cases in Ontario) reflects a specific surveillance period and may not represent current rates.","value_numeric":null},{"paper_doi":"10.1503/cmaj.260142","tag_type":"warning","value":"Myocarditis was diagnosed by cardiac MRI without endomyocardial biopsy, so histopathologic confirmation is absent.","value_numeric":null},{"paper_doi":"10.1503/cmaj.260142","tag_type":"warning","value":"Single case report — findings should not be generalized without supporting evidence from larger studies.","value_numeric":null},{"paper_doi":"10.1503/cmaj.260142","tag_type":"warning","value":"The patient was on azathioprine (immunosuppressed), which may have contributed to disease severity; applicability to immunocompetent patients is uncertain.","value_numeric":null}],"summaries":{"what_studied":"A case report of a 79-year-old immunocompromised man from rural eastern Ontario who presented in July with fever, cytopenias, and multiorgan dysfunction. The case examines the clinical course, diagnostic workup, and treatment of *Anaplasma phagocytophilum* infection complicated by acute myocarditis.","key_result":"PCR-confirmed anaplasmosis with associated acute myocarditis (EF 43%, basal inferolateral LGE on cardiac MRI) resolved fully with 14 days of oral doxycycline 100 mg twice daily; repeat TTE at 4 months showed normalized ventricular function.","limitations":"- Single case report; cannot establish causation or generalizability.\n- Lumbar puncture was contraindicated due to thrombocytopenia, so CNS infection could not be fully excluded.\n- Endomyocardial biopsy was not performed; myocarditis diagnosis rests on clinical and cardiac MRI findings.","practice_takeaway":"In febrile patients from tick-endemic regions with thrombocytopenia, lymphopenia, and elevated transaminases — even without recalled tick exposure — start empiric doxycycline early and investigate for anaplasmosis. If cardiac symptoms or elevated troponin/BNP emerge, obtain echocardiography and cardiac MRI; myocarditis from anaplasmosis can resolve completely with appropriate antibiotic therapy."}},{"doi":"10.1136/sextrans-2025-056746","pmid":"42392875","title":"Acceptability and use of doxyPEP among cisgender men who have sex with men, transgender women and non-binary persons assigned male sex at birth: results from a national online survey from the USA","journal_title":"Sexually Transmitted Infections","journal_issn":"1368-4973","published_at":"2026-07-02T00:00:00.000Z","url":"https://doi.org/10.1136/sextrans-2025-056746","source_score":8,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-07-05T13:38:48.247Z","updated_at":"2026-07-05T13:38:48.247Z","tags":[{"paper_doi":"10.1136/sextrans-2025-056746","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1136/sextrans-2025-056746","tag_type":"category","value":"Infectious Diseases","value_numeric":null},{"paper_doi":"10.1136/sextrans-2025-056746","tag_type":"condition","value":"HIV","value_numeric":null},{"paper_doi":"10.1136/sextrans-2025-056746","tag_type":"condition","value":"Sexually Transmitted Infections","value_numeric":null},{"paper_doi":"10.1136/sextrans-2025-056746","tag_type":"generic","value":"doxycycline","value_numeric":null},{"paper_doi":"10.1136/sextrans-2025-056746","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1136/sextrans-2025-056746","tag_type":"level_of_evidence","value":"4","value_numeric":null},{"paper_doi":"10.1136/sextrans-2025-056746","tag_type":"modality","value":"Post-Exposure Prophylaxis","value_numeric":null},{"paper_doi":"10.1136/sextrans-2025-056746","tag_type":"sample_size","value":"n=471","value_numeric":471},{"paper_doi":"10.1136/sextrans-2025-056746","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1136/sextrans-2025-056746","tag_type":"study_design","value":"Cross-Sectional Survey","value_numeric":null},{"paper_doi":"10.1136/sextrans-2025-056746","tag_type":"warning","value":"Sample was recruited exclusively via one MSM social networking app, which likely over-represents tech-savvy, urban, and already health-engaged individuals — uptake estimates may not reflect the broader eligible US population.","value_numeric":null},{"paper_doi":"10.1136/sextrans-2025-056746","tag_type":"warning","value":"The survey predates the 2023 CDC doxyPEP guidelines; reported use rates serve as a pre-guideline baseline and may not reflect current practice.","value_numeric":null},{"paper_doi":"10.1136/sextrans-2025-056746","tag_type":"warning","value":"Total sample size tag uses the eligible analytic cohort (n=471); the full respondent pool was 1,428 — both figures appear in the abstract.","value_numeric":null}],"summaries":{"what_studied":"A national cross-sectional online survey (March–April 2023) evaluated doxyPEP interest, use, and associated factors among 471 eligible cisgender MSM, transgender women, and non-binary persons assigned male sex at birth in the USA who had a bacterial STI in the prior year.","key_result":"Among eligible respondents (n=471), only 17% had ever used doxyPEP and 2.5% were current users, despite 88.3% of non-users expressing interest. Black race (aOR 3.08), higher partner count (aOR 1.02 per partner), current PrEP use (aOR 3.61), and living with HIV (aOR 3.08) were independently associated with doxyPEP use.","limitations":"Self-selected convenience sample recruited via a single MSM social networking app may not represent all eligible populations; survey conducted before CDC national guidelines existed, limiting generalizability to current practice; self-reported STI history used to define eligibility without clinical verification.","practice_takeaway":"Most at-risk MSM and transgender/non-binary patients want doxyPEP but haven't used it — proactively offer it, especially to patients already on PrEP or living with HIV, who appear most likely to engage. Awareness and access gaps, not disinterest, are the primary barrier."}},{"doi":"10.1093/cid/ciag317","pmid":"42142880","title":"A randomized clinical trial to compare moxiFloxAcin veRsus aziTHromycin for the trEatment of MycoplaSma geniTalium: the FARTHEST Study","journal_title":"Clinical Infectious Diseases","journal_issn":"1058-4838","published_at":"2026-05-17T00:00:00.000Z","url":"https://doi.org/10.1093/cid/ciag317","source_score":11,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-05-23T13:24:58.379Z","updated_at":"2026-05-23T13:24:58.379Z","tags":[{"paper_doi":"10.1093/cid/ciag317","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1093/cid/ciag317","tag_type":"category","value":"Infectious Diseases","value_numeric":null},{"paper_doi":"10.1093/cid/ciag317","tag_type":"condition","value":"Mycoplasma Genitalium Infection","value_numeric":null},{"paper_doi":"10.1093/cid/ciag317","tag_type":"generic","value":"azithromycin","value_numeric":null},{"paper_doi":"10.1093/cid/ciag317","tag_type":"generic","value":"doxycycline","value_numeric":null},{"paper_doi":"10.1093/cid/ciag317","tag_type":"generic","value":"moxifloxacin","value_numeric":null},{"paper_doi":"10.1093/cid/ciag317","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1093/cid/ciag317","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1093/cid/ciag317","tag_type":"modality","value":"Fluoroquinolone","value_numeric":null},{"paper_doi":"10.1093/cid/ciag317","tag_type":"modality","value":"Macrolide","value_numeric":null},{"paper_doi":"10.1093/cid/ciag317","tag_type":"sample_size","value":"n=358","value_numeric":358},{"paper_doi":"10.1093/cid/ciag317","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1093/cid/ciag317","tag_type":"study_design","value":"Randomized Controlled Trial","value_numeric":null},{"paper_doi":"10.1093/cid/ciag317","tag_type":"warning","value":"Open-label design may introduce performance or detection bias despite randomization.","value_numeric":null},{"paper_doi":"10.1093/cid/ciag317","tag_type":"warning","value":"Resistance genotyping was not performed; it is unclear how cure rates would differ in macrolide-resistant vs. susceptible strains.","value_numeric":null},{"paper_doi":"10.1093/cid/ciag317","tag_type":"warning","value":"Single-center study — results may not generalize to populations with different resistance prevalence profiles.","value_numeric":null},{"paper_doi":"10.1093/cid/ciag317","tag_type":"warning","value":"The paper's DOI suffix 'ciag317' and 2026 publication date are noted; this is a recently published trial and guidelines may not yet reflect these findings.","value_numeric":null}],"summaries":{"what_studied":"This RCT compared moxifloxacin 400 mg/day × 10 days vs. azithromycin 500 mg/day × 6 days for microbiological cure of *Mycoplasma genitalium* (MG) in adults detected by multiplex PCR, without resistance-guided testing; TOC was performed ≥28 days post-treatment (n=358).","key_result":"Moxifloxacin achieved microbiological cure in 87.0% vs. 61.2% with azithromycin (ITT; absolute risk difference 25.8%, 95% CI 16.5–35.2); superiority was confirmed in both ITT and per-protocol analyses. Azithromycin showed comparable efficacy only in heterosexual individuals. Doxycycline co-administration did not improve outcomes. Both regimens were well tolerated (1 discontinuation total).","limitations":"- Single-center (monocentric) design limits generalizability.\n- Open-label trial introduces potential assessment bias.\n- Resistance genotyping was not performed, so cure rates stratified by resistance profile are unknown.","practice_takeaway":"When *Mycoplasma genitalium* resistance assays are unavailable, moxifloxacin (400 mg × 10 days) is superior to azithromycin and should be considered as a first-line option. Routine doxycycline co-administration does not add benefit."}},{"doi":"10.1016/s1473-3099(26)00123-4","pmid":"42107388","title":"Durability of doxycycline effectiveness against gonorrhoea after implementation of post-exposure prophylaxis in southern California, USA: a retrospective, test-negative, observational study","journal_title":"The Lancet Infectious Diseases","journal_issn":"1473-3099","published_at":"2026-05-07T00:00:00.000Z","url":"https://doi.org/10.1016/s1473-3099(26)00123-4","source_score":15,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-05-13T13:19:25.857Z","updated_at":"2026-05-13T13:19:25.857Z","tags":[{"paper_doi":"10.1016/s1473-3099(26)00123-4","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1016/s1473-3099(26)00123-4","tag_type":"category","value":"Infectious Diseases","value_numeric":null},{"paper_doi":"10.1016/s1473-3099(26)00123-4","tag_type":"condition","value":"Antimicrobial Resistance","value_numeric":null},{"paper_doi":"10.1016/s1473-3099(26)00123-4","tag_type":"condition","value":"Chlamydia","value_numeric":null},{"paper_doi":"10.1016/s1473-3099(26)00123-4","tag_type":"condition","value":"Gonorrhoea","value_numeric":null},{"paper_doi":"10.1016/s1473-3099(26)00123-4","tag_type":"condition","value":"Sexually Transmitted Infections","value_numeric":null},{"paper_doi":"10.1016/s1473-3099(26)00123-4","tag_type":"condition","value":"Syphilis","value_numeric":null},{"paper_doi":"10.1016/s1473-3099(26)00123-4","tag_type":"generic","value":"doxycycline","value_numeric":null},{"paper_doi":"10.1016/s1473-3099(26)00123-4","tag_type":"impact_flag","value":"safety_signal","value_numeric":null},{"paper_doi":"10.1016/s1473-3099(26)00123-4","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1016/s1473-3099(26)00123-4","tag_type":"modality","value":"Post-Exposure Prophylaxis","value_numeric":null},{"paper_doi":"10.1016/s1473-3099(26)00123-4","tag_type":"modality","value":"Tetracycline Antibiotic","value_numeric":null},{"paper_doi":"10.1016/s1473-3099(26)00123-4","tag_type":"sample_size","value":"n=26582","value_numeric":26582},{"paper_doi":"10.1016/s1473-3099(26)00123-4","tag_type":"sex","value":"male","value_numeric":null},{"paper_doi":"10.1016/s1473-3099(26)00123-4","tag_type":"study_design","value":"Retrospective Observational Study (Test-Negative Design)","value_numeric":null},{"paper_doi":"10.1016/s1473-3099(26)00123-4","tag_type":"warning","value":"Effectiveness estimates for gonorrhoea sub-periods have wide confidence intervals, particularly for early pre-implementation phase (95% CI 2.7–65.8), limiting precision of temporal trend conclusions.","value_numeric":null},{"paper_doi":"10.1016/s1473-3099(26)00123-4","tag_type":"warning","value":"The study includes transgender women assigned male at birth, but sex tag is marked 'male' per biological assignment used in eligibility criteria — clinicians should note this population distinction.","value_numeric":null},{"paper_doi":"10.1016/s1473-3099(26)00123-4","tag_type":"warning","value":"The test-negative design controls for healthcare-seeking behaviour but cannot fully adjust for unmeasured sexual risk behaviour differences between doxy-PEP users and non-users.","value_numeric":null}],"summaries":{"what_studied":"This retrospective, test-negative observational study evaluated real-world effectiveness of doxycycline post-exposure prophylaxis (doxy-PEP) against chlamydia, gonorrhoea, and syphilis among 26,582 MSM and transgender women in Kaiser Permanente Southern California (Jan 2023–Jun 2025), and whether gonorrhoea effectiveness was durable over time as tetracycline resistance spread.","key_result":"Doxy-PEP was effective against chlamydia (66.5%, 95% CI 53.6–75.9) and syphilis (60.7%, 95% CI 28.3–78.5), but showed no meaningful protection against gonorrhoea overall (−1.8%, 95% CI −18.5 to 12.5). Gonorrhoea effectiveness dropped from 42.3% before statewide implementation to −15.0% by Jan–Jun 2025, closely tracking a rise in tetM prevalence: effectiveness fell from 47.2% when tetM was present in 20–29.9% of isolates to −8.5% when tetM reached ≥50% of isolates.","limitations":"- Observational design cannot fully exclude confounding (e.g., sexual behaviour differences between doxy-PEP users and non-users).\n- tetM prevalence data were derived from local surveillance isolates, which may not perfectly represent the full circulating strain population.\n- Doxy-PEP use was defined by prescription fills, not confirmed adherence or timing of doses.","practice_takeaway":"Clinicians prescribing doxy-PEP should counsel MSM and transgender women that protection against gonorrhoea may be minimal or absent in settings where tetracycline-resistant *N. gonorrhoeae* is prevalent (≥50% tetM). Sustained benefits against chlamydia and syphilis remain, so risk-benefit discussions should be individualized and local AMR surveillance data should inform ongoing doxy-PEP recommendations."}},{"doi":"10.2147/ccid.s596249","pmid":"42079476","title":"Morbihan Disease May Induce Nonspecific Inflammatory of Extra-Facial Region: A Case Report and Literature Review","journal_title":"Clinical, Cosmetic and Investigational Dermatology","journal_issn":"1178-7015","published_at":"2026-05-04T00:00:00.000Z","url":"https://doi.org/10.2147/ccid.s596249","source_score":32,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2026-04-28","doi":"10.2147/ccid.s596249","days":"30","issn":"1178-7015","rank":"9","field":"Clinical Medicine","score":"32","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.2147/CCID.S596249","title":"Morbihan Disease May Induce Nonspecific Inflammatory of Extra-Facial Region: A Case Report and Literature Review.","journal":"Clinical, cosmetic and investigational dermatology","methods":"","results":"","abstract":"$30","keywords":["Morbihan disease","case report","literature review"],"pubmed_id":"42079476","conclusions":"","publication_date":"2026-05-04T00:00:00"},"crossref":{"DOI":"10.2147/ccid.s596249","URL":"https://doi.org/10.2147/ccid.s596249","ISSN":["1178-7015"],"link":[{"URL":"https://www.dovepress.com/article/download/114534","content-type":"application/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https://www.dovepress.com/article/download/114534","content-type":"application/pdf","content-version":"vor","intended-application":"similarity-checking"}],"page":"1-6","type":"journal-article","issue":null,"score":1,"title":["Morbihan Disease May Induce Nonspecific Inflammatory of Extra-Facial Region: A Case Report and Literature Review"],"author":[{"given":"FeiFang","family":"Deng","sequence":"first","affiliation":[]},{"given":"Peng","family":"Wang","sequence":"additional","affiliation":[]}],"issued":{"date-parts":[[2026,4]]},"member":"301","prefix":"10.2147","source":"Crossref","volume":"Volume 19","created":{"date-time":"2026-04-27T03:20:12Z","timestamp":1777260012000,"date-parts":[[2026,4,27]]},"indexed":{"date-time":"2026-04-27T03:38:32Z","timestamp":1777261112468,"date-parts":[[2026,4,27]]},"license":[{"URL":"https://creativecommons.org/licenses/by-nc/3.0/","start":{"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000,"date-parts":[[2026,4,1]]},"delay-in-days":0,"content-version":"unspecified"}],"subject":[],"abstract":null,"language":"en","relation":{},"resource":{"primary":{"URL":"https://www.dovepress.com/morbihan-disease-may-induce-nonspecific-inflammatory-of-extra-facial-r-peer-reviewed-fulltext-article-CCID"}},"subtitle":[],"deposited":{"date-time":"2026-04-27T03:20:14Z","timestamp":1777260014000,"date-parts":[[2026,4,27]]},"issn-type":[{"type":"electronic","value":"1178-7015"}],"published":{"date-parts":[[2026,4]]},"publisher":"Informa UK Limited","reference":[{"DOI":"10.1111/j.1365-2230.2008.02892.x","key":"ref1","year":"2008","issue":null,"author":"Nagasaka","volume":"33","first-page":"764","unstructured":null,"article-title":null,"journal-title":"Clin Exp Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1007/s11606-022-07858-x","key":"ref2","year":"2023","issue":null,"author":"Suzuki","volume":"38","first-page":"233","unstructured":null,"article-title":null,"journal-title":"J Gen Intern Med","doi-asserted-by":"publisher"},{"DOI":"10.4103/ijdvl.IJDVL_1004_18","key":"ref3","year":"2020","issue":null,"author":"Singh","volume":"86","first-page":"418","unstructured":null,"article-title":null,"journal-title":"Indian J Dermatol Venereol Leprol","doi-asserted-by":"publisher"},{"DOI":"10.5070/D37RC0M3KS","key":"ref4","year":"2012","issue":null,"author":"Hu","volume":"18","first-page":"27","unstructured":null,"article-title":null,"journal-title":"Dermatol Online J","doi-asserted-by":"publisher"},{"DOI":"10.7181/acfs.2021.00185","key":"ref5","year":"2021","issue":null,"author":"Kim","volume":"22","first-page":"131","unstructured":null,"article-title":null,"journal-title":"Arch craniofacial Surg","doi-asserted-by":"publisher"},{"DOI":"10.12659/AJCR.943421","key":"ref6","year":"2024","issue":null,"author":"Di Maria","volume":"25","first-page":"e943421","unstructured":null,"article-title":null,"journal-title":"Am J Case Rep","doi-asserted-by":"publisher"},{"DOI":null,"key":"ref7","year":"2023","issue":null,"author":"van der Linden","volume":"16","first-page":"22","unstructured":null,"article-title":null,"journal-title":"J Clin Aesthet Dermatol","doi-asserted-by":null},{"DOI":"10.1016/j.jdcr.2023.06.004","key":"ref8","year":"2023","issue":null,"author":"Woodbury","volume":"38","first-page":"102","unstructured":null,"article-title":null,"journal-title":"JAAD case reports","doi-asserted-by":"publisher"},{"DOI":"10.5070/D3266049317","key":"ref9","year":"2020","issue":null,"author":"Kuraitis","volume":"26","first-page":null,"unstructured":null,"article-title":null,"journal-title":"Dermatol Online J","doi-asserted-by":"publisher"},{"DOI":"10.2340/actadv.v105.43599","key":"ref10","year":"2025","issue":null,"author":"Kaiser","volume":"105","first-page":"adv43599","unstructured":null,"article-title":null,"journal-title":"Acta Derm Venereol","doi-asserted-by":"publisher"},{"DOI":"10.15586/aei.v52i2.978","key":"ref11","year":"2024","issue":null,"author":"Mazurek-Durlak","volume":"52","first-page":"23","unstructured":null,"article-title":null,"journal-title":"Allergol Immunopathol","doi-asserted-by":"publisher"}],"short-title":[],"content-domain":{"domain":[],"crossmark-restriction":false},"original-title":[],"container-title":["Clinical, Cosmetic and Investigational Dermatology"],"reference-count":11,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2026,4]]},"references-count":11,"short-container-title":["CCID"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.2147/ccid.s596249","is_oa":true,"title":"Morbihan Disease May Induce Nonspecific Inflammatory of Extra-Facial Region: A Case Report and Literature Review","updated":"2026-05-08T16:02:47+00:00","published_date":"2026-04-01","best_oa_location":{"url":"https://doi.org/10.2147/ccid.s596249","pmh_id":null,"url_for_pdf":null,"url_for_landing_page":"https://doi.org/10.2147/ccid.s596249"}}},"created_at":"2026-05-07T17:34:09.240Z","updated_at":"2026-05-14T15:13:26.918Z","tags":[{"paper_doi":"10.2147/ccid.s596249","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.2147/ccid.s596249","tag_type":"brand","value":"Xolair","value_numeric":null},{"paper_doi":"10.2147/ccid.s596249","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.2147/ccid.s596249","tag_type":"condition","value":"Morbihan Disease","value_numeric":null},{"paper_doi":"10.2147/ccid.s596249","tag_type":"condition","value":"Rosacea","value_numeric":null},{"paper_doi":"10.2147/ccid.s596249","tag_type":"generic","value":"azelaic acid","value_numeric":null},{"paper_doi":"10.2147/ccid.s596249","tag_type":"generic","value":"baricitinib","value_numeric":null},{"paper_doi":"10.2147/ccid.s596249","tag_type":"generic","value":"doxycycline","value_numeric":null},{"paper_doi":"10.2147/ccid.s596249","tag_type":"generic","value":"isotretinoin","value_numeric":null},{"paper_doi":"10.2147/ccid.s596249","tag_type":"generic","value":"omalizumab","value_numeric":null},{"paper_doi":"10.2147/ccid.s596249","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.2147/ccid.s596249","tag_type":"level_of_evidence","value":"4","value_numeric":null},{"paper_doi":"10.2147/ccid.s596249","tag_type":"modality","value":"Anti-IgE Monoclonal Antibody","value_numeric":null},{"paper_doi":"10.2147/ccid.s596249","tag_type":"modality","value":"Intense Pulsed Light","value_numeric":null},{"paper_doi":"10.2147/ccid.s596249","tag_type":"modality","value":"JAK Inhibitor","value_numeric":null},{"paper_doi":"10.2147/ccid.s596249","tag_type":"modality","value":"Retinoid","value_numeric":null},{"paper_doi":"10.2147/ccid.s596249","tag_type":"modality","value":"Tetracycline Antibiotic","value_numeric":null},{"paper_doi":"10.2147/ccid.s596249","tag_type":"sample_size","value":"n=80","value_numeric":80},{"paper_doi":"10.2147/ccid.s596249","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.2147/ccid.s596249","tag_type":"study_design","value":"Case Report with Literature Review","value_numeric":null},{"paper_doi":"10.2147/ccid.s596249","tag_type":"warning","value":"Attribution of extra-facial lesions to Morbihan disease is presumptive; biopsy showed only nonspecific inflammation with no pathognomonic features, and other causes were excluded by clinical reasoning rather than exhaustive workup.","value_numeric":null},{"paper_doi":"10.2147/ccid.s596249","tag_type":"warning","value":"Omalizumab brand 'Xolair' is inferred from the generic name; the paper does not explicitly state the brand name.","value_numeric":null},{"paper_doi":"10.2147/ccid.s596249","tag_type":"warning","value":"The median age reported in the abstract is 54 years, but Table 1 in the full text lists 55 (IQR 43–62) — minor discrepancy noted.","value_numeric":null},{"paper_doi":"10.2147/ccid.s596249","tag_type":"warning","value":"The study design is labeled 'Case Report with Literature Review' — the pooled statistical analysis (ORs) is derived from aggregated case reports, not a formal systematic review or meta-analysis, limiting reliability of prognostic estimates.","value_numeric":null}],"summaries":{"what_studied":"A case report of a 29-year-old man with Morbihan disease (associated with rosacea) who developed novel extra-facial nonspecific inflammatory lesions (thighs, trunk, upper limbs), combined with a literature review of 80 patients (2004–2025) examining clinical features, histopathology, and treatment outcomes.","key_result":"Long-term isotretinoin (20 mg twice daily, tapered over ~3 years) achieved sustained facial and extra-facial remission without relapse. In the pooled literature cohort (n=80), lymphatic/vascular dilation on biopsy predicted favorable outcomes (OR 6.00, 95% CI 1.57–22.96, p=0.007), while dermal edema (OR 0.167, p=0.007) and granuloma (OR 0.321, p=0.037) predicted poorer response. Of 24 isotretinoin-treated patients, 15 improved; all 4 omalizumab-treated patients responded.","limitations":"- Evidence base is entirely retrospective case reports/series, precluding any definitive treatment hierarchy.\n- Literature search restricted to English-language publications, introducing potential language bias.\n- Extra-facial lesion attribution to Morbihan disease is presumptive (biopsy showed only nonspecific inflammation; no definitive causal link established).","practice_takeaway":"Consider long-term low-dose isotretinoin as a first-line option in refractory Morbihan disease; omalizumab and IPL may offer partial benefit as adjuncts. Histopathological findings (lymphatic/vascular dilation vs. dermal edema or granuloma) may help predict treatment response, though data are exploratory only."}},{"doi":"10.1093/ofid/ofag253","pmid":null,"title":"Beta-Lactam plus Azithromycin or Doxycycline versus Fluoroquinolones in Hospitalized Adult Patients with Community-Acquired Pneumonia: A Systematic Review and Network Meta-Analysis","journal_title":"Open Forum Infectious Diseases","journal_issn":"2328-8957","published_at":"2026-05-01T00:00:00.000Z","url":"https://doi.org/10.1093/ofid/ofag253","source_score":10,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":false,"crossref":true,"unpaywall":true},"created_at":"2026-05-07T22:50:44.846Z","updated_at":"2026-05-07T22:50:44.846Z","tags":[{"paper_doi":"10.1093/ofid/ofag253","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1093/ofid/ofag253","tag_type":"brand","value":"Avelox","value_numeric":null},{"paper_doi":"10.1093/ofid/ofag253","tag_type":"brand","value":"Levaquin","value_numeric":null},{"paper_doi":"10.1093/ofid/ofag253","tag_type":"brand","value":"Zithromax","value_numeric":null},{"paper_doi":"10.1093/ofid/ofag253","tag_type":"category","value":"Infectious Diseases","value_numeric":null},{"paper_doi":"10.1093/ofid/ofag253","tag_type":"condition","value":"Community-Acquired Pneumonia","value_numeric":null},{"paper_doi":"10.1093/ofid/ofag253","tag_type":"generic","value":"azithromycin","value_numeric":null},{"paper_doi":"10.1093/ofid/ofag253","tag_type":"generic","value":"doxycycline","value_numeric":null},{"paper_doi":"10.1093/ofid/ofag253","tag_type":"generic","value":"levofloxacin","value_numeric":null},{"paper_doi":"10.1093/ofid/ofag253","tag_type":"generic","value":"moxifloxacin","value_numeric":null},{"paper_doi":"10.1093/ofid/ofag253","tag_type":"impact_flag","value":"confirms_prior","value_numeric":null},{"paper_doi":"10.1093/ofid/ofag253","tag_type":"level_of_evidence","value":"1","value_numeric":null},{"paper_doi":"10.1093/ofid/ofag253","tag_type":"modality","value":"Beta-Lactam Antibiotic","value_numeric":null},{"paper_doi":"10.1093/ofid/ofag253","tag_type":"modality","value":"Fluoroquinolone","value_numeric":null},{"paper_doi":"10.1093/ofid/ofag253","tag_type":"modality","value":"Macrolide","value_numeric":null},{"paper_doi":"10.1093/ofid/ofag253","tag_type":"modality","value":"Tetracycline","value_numeric":null},{"paper_doi":"10.1093/ofid/ofag253","tag_type":"sample_size","value":"n=186,789","value_numeric":186789},{"paper_doi":"10.1093/ofid/ofag253","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1093/ofid/ofag253","tag_type":"study_design","value":"Systematic Review and Network Meta-Analysis","value_numeric":null},{"paper_doi":"10.1093/ofid/ofag253","tag_type":"warning","value":"GRADE certainty of evidence ratings for individual outcomes are not specified in the abstract; confidence in these findings may vary by outcome.","value_numeric":null},{"paper_doi":"10.1093/ofid/ofag253","tag_type":"warning","value":"Network meta-analysis nodes included 4 regimens but the number of direct comparisons between each pair is uneven, which may affect precision of indirect estimates.","value_numeric":null},{"paper_doi":"10.1093/ofid/ofag253","tag_type":"warning","value":"The total sample size combines a small RCT pool (n=861) with a large non-randomized pool (n=185,928); results are heavily weighted by observational data, which may limit causal inference.","value_numeric":null}],"summaries":{"key_result":"No statistically significant differences were found between beta-lactam + azithromycin and beta-lactam + doxycycline for in-hospital mortality, ICU admission, need for invasive mechanical ventilation, *C. difficile* infection, or QT prolongation — across both direct comparisons and network meta-analysis.","what_studied":"This systematic review and network meta-analysis compared beta-lactam + azithromycin vs. beta-lactam + doxycycline vs. fluoroquinolones (levofloxacin, moxifloxacin) for hospitalized adults with CAP, pooling 20 studies (6 RCTs, 14 non-randomized) across databases up to June 2024.","limitations":"- The 6 RCTs enrolled only 861 participants, limiting power for rare outcomes.\n- The 14 non-randomized studies (n=185,928) are subject to confounding and heterogeneity in patient populations.\n- No head-to-head RCTs directly comparing azithromycin vs. doxycycline as the add-on agent were identified.","practice_takeaway":"For hospitalized adults with CAP on a beta-lactam backbone, doxycycline appears to be an equally effective alternative to azithromycin with a similar safety profile — a useful option when azithromycin resistance or cardiac concerns arise. Clinicians can consider either agent with similar confidence until direct RCT data are available."}},{"doi":"10.1001/jamasurg.2026.0613","pmid":"41920556","title":"American Society of Breast Surgeons, Society of Breast Imaging, and College of American Pathology 2025 Guidelines for the Management of Infectious and Inflammatory Lesions of the Breast","journal_title":"JAMA Surgery","journal_issn":"2168-6254","published_at":"2026-04-01T00:00:00.000Z","url":"https://doi.org/10.1001/jamasurg.2026.0613","source_score":42,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-06-14T13:34:45.786Z","updated_at":"2026-06-14T13:34:45.786Z","tags":[{"paper_doi":"10.1001/jamasurg.2026.0613","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1001/jamasurg.2026.0613","tag_type":"category","value":"Surgery","value_numeric":null},{"paper_doi":"10.1001/jamasurg.2026.0613","tag_type":"condition","value":"Breast Abscess","value_numeric":null},{"paper_doi":"10.1001/jamasurg.2026.0613","tag_type":"condition","value":"Cystic Neutrophilic Granulomatous Mastitis","value_numeric":null},{"paper_doi":"10.1001/jamasurg.2026.0613","tag_type":"condition","value":"Granulomatous Mastitis","value_numeric":null},{"paper_doi":"10.1001/jamasurg.2026.0613","tag_type":"condition","value":"Lactational Mastitis","value_numeric":null},{"paper_doi":"10.1001/jamasurg.2026.0613","tag_type":"condition","value":"Periductal Mastitis","value_numeric":null},{"paper_doi":"10.1001/jamasurg.2026.0613","tag_type":"generic","value":"azathioprine","value_numeric":null},{"paper_doi":"10.1001/jamasurg.2026.0613","tag_type":"generic","value":"doxycycline","value_numeric":null},{"paper_doi":"10.1001/jamasurg.2026.0613","tag_type":"generic","value":"methotrexate","value_numeric":null},{"paper_doi":"10.1001/jamasurg.2026.0613","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1001/jamasurg.2026.0613","tag_type":"level_of_evidence","value":"5","value_numeric":null},{"paper_doi":"10.1001/jamasurg.2026.0613","tag_type":"modality","value":"Antibiotic","value_numeric":null},{"paper_doi":"10.1001/jamasurg.2026.0613","tag_type":"modality","value":"Biologic / Immunosuppressive Agent","value_numeric":null},{"paper_doi":"10.1001/jamasurg.2026.0613","tag_type":"modality","value":"Intralesional Corticosteroid Injection","value_numeric":null},{"paper_doi":"10.1001/jamasurg.2026.0613","tag_type":"sex","value":"female","value_numeric":null},{"paper_doi":"10.1001/jamasurg.2026.0613","tag_type":"study_design","value":"Clinical Practice Guideline","value_numeric":null},{"paper_doi":"10.1001/jamasurg.2026.0613","tag_type":"warning","value":"Level of evidence is assigned as 5 (expert opinion/consensus) due to the acknowledged scarcity of RCT data; the paper does not explicitly state a numbered LOE hierarchy.","value_numeric":null},{"paper_doi":"10.1001/jamasurg.2026.0613","tag_type":"warning","value":"No sample size is reported — this is a consensus guideline, not a primary study with enrolled patients.","value_numeric":null},{"paper_doi":"10.1001/jamasurg.2026.0613","tag_type":"warning","value":"Study design labeled as 'Clinical Practice Guideline' — the abstract does not describe a formal systematic review or GRADE methodology, which may limit the strength of individual recommendations.","value_numeric":null}],"summaries":{"what_studied":"An expert panel from ASBrS, SBI, and CAP developed consensus guidelines for managing the three most common infectious/inflammatory breast conditions: lactational mastitis (LM), granulomatous mastitis (GM), and periductal mastitis with squamous metaplasia of lactiferous ducts (PDM-SMOLD).","key_result":"Key recommendations include: (1) infectious LM typically requires stab incision + drain (no packing), not operative drainage; (2) GM requires core biopsy confirmation — cystic neutrophilic GM (CNGM) should be treated empirically with doxycycline, while non-CNGM cases have no role for empiric antibiotics; recurrent/worsening GM should be treated with repeat intralesional steroids (avoid surgical excision); (3) PDM-SMOLD fistulas require radial excision of diseased ducts.","limitations":"Guidelines are based on expert consensus and opinion rather than high-quality RCT evidence, reflecting the scarcity of evidence-based data for these conditions. No formal systematic review or graded evidence hierarchy is described in the abstract.","practice_takeaway":"Avoid routine operative drainage for lactational breast abscesses — office-based stab incision with drain is preferred. For recurrent granulomatous mastitis, repeat intralesional steroid injections are first-line; surgical excision should be avoided."}},{"doi":"10.1016/j.jaad.2025.02.028","pmid":"40112894","title":"Efficacy and tolerability of low-dose versus high-dose doxycycline in the management of lymphocytic scarring alopecias","journal_title":"Journal of the American Academy of Dermatology","journal_issn":"0190-9622","published_at":"2025-03-21T00:00:00.000Z","url":"https://doi.org/10.1016/j.jaad.2025.02.028","source_score":557,"is_retracted":false,"is_open_access":false,"raw_metadata":{"ooir":{"day":"2025-03-24","doi":"10.1016/j.jaad.2025.02.028","days":"30","issn":"0190-9622","rank":"1","field":"Clinical Medicine","score":"557","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1016/j.jaad.2025.02.028","title":"Efficacy and tolerability of low-dose versus high-dose doxycycline in the management of lymphocytic scarring alopecias.","journal":"Journal of the American Academy of Dermatology","methods":"","results":"","abstract":"","keywords":["adverse effects","antimicrobial stewardship","central centrifugal cicatricial alopecia","doxycycline","frontal fibrosing alopecia","lichen planopilaris","scarring alopecia","subantimicrobial dosing"],"pubmed_id":"40112894","conclusions":"","publication_date":"2025-03-21T00:00:00"},"crossref":{"DOI":"10.1016/j.jaad.2025.02.028","URL":"https://doi.org/10.1016/j.jaad.2025.02.028","ISSN":["0190-9622"],"link":[{"URL":"https://api.elsevier.com/content/article/PII:S0190962225003044?httpAccept=text/xml","content-type":"text/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https://api.elsevier.com/content/article/PII:S0190962225003044?httpAccept=text/plain","content-type":"text/plain","content-version":"vor","intended-application":"text-mining"}],"page":"1431-1433","type":"journal-article","issue":"6","score":1,"title":["Efficacy and tolerability of low-dose versus high-dose doxycycline in the management of lymphocytic scarring alopecias"],"author":[{"given":"Carli","family":"Needle","sequence":"first","affiliation":[]},{"given":"Anna","family":"Brinks","sequence":"additional","affiliation":[]},{"given":"Akshay","family":"Pulavarty","sequence":"additional","affiliation":[]},{"given":"Caitlin","family":"Kearney","sequence":"additional","affiliation":[]},{"given":"Ambika","family":"Nohria","sequence":"additional","affiliation":[]},{"given":"Deesha","family":"Desai","sequence":"additional","affiliation":[]},{"given":"Jerry","family":"Shapiro","sequence":"additional","affiliation":[]},{"given":"Kristen","family":"Lo Sicco","sequence":"additional","affiliation":[]}],"issued":{"date-parts":[[2025,6]]},"member":"78","prefix":"10.1016","source":"Crossref","volume":"92","created":{"date-time":"2025-03-18T05:17:28Z","timestamp":1742275048000,"date-parts":[[2025,3,18]]},"indexed":{"date-time":"2025-07-09T22:56:50Z","timestamp":1752101810356,"date-parts":[[2025,7,9]]},"license":[{"URL":"https://www.elsevier.com/tdm/userlicense/1.0/","start":{"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000,"date-parts":[[2025,6,1]]},"delay-in-days":0,"content-version":"tdm"},{"URL":"https://www.elsevier.com/legal/tdmrep-license","start":{"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000,"date-parts":[[2025,6,1]]},"delay-in-days":0,"content-version":"tdm"}],"subject":[],"abstract":null,"language":"en","relation":{},"resource":{"primary":{"URL":"https://linkinghub.elsevier.com/retrieve/pii/S0190962225003044"}},"subtitle":[],"assertion":[{"name":"publisher","label":"This article is maintained by","value":"Elsevier"},{"name":"articletitle","label":"Article Title","value":"Efficacy and tolerability of low-dose versus high-dose doxycycline in the management of lymphocytic scarring alopecias"},{"name":"journaltitle","label":"Journal Title","value":"Journal of the American Academy of Dermatology"},{"name":"articlelink","label":"CrossRef DOI link to publisher maintained version","value":"https://doi.org/10.1016/j.jaad.2025.02.028"},{"name":"content_type","label":"Content Type","value":"article"},{"name":"copyright","label":"Copyright","value":"© 2025 The Author(s). Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies."}],"deposited":{"date-time":"2025-05-19T20:10:47Z","timestamp":1747685447000,"date-parts":[[2025,5,19]]},"issn-type":[{"type":"print","value":"0190-9622"}],"published":{"date-parts":[[2025,6]]},"publisher":"Elsevier BV","reference":[{"DOI":"10.1016/j.jaad.2024.01.086","key":"10.1016/j.jaad.2025.02.028_bib1","year":"2024","issue":"2","author":"Obi","volume":"91","first-page":"331","unstructured":null,"article-title":"Doxycycline for central centrifugal cicatricial alopecia: a single center retrospective analysis","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jdcr.2015.06.013","key":"10.1016/j.jaad.2025.02.028_bib2","year":"2015","issue":"5","author":"Chen","volume":"1","first-page":"289","unstructured":null,"article-title":"Successful treatment of epidermal growth factor receptor inhibitor-induced alopecia with doxycycline","journal-title":"JAAD Case Rep","doi-asserted-by":"crossref"},{"DOI":"10.1001/archderm.139.4.459","key":"10.1016/j.jaad.2025.02.028_bib3","year":"2003","issue":"4","author":"Skidmore","volume":"139","first-page":"459","unstructured":null,"article-title":"Effects of subantimicrobial-dose doxycycline in the treatment of moderate acne","journal-title":"Arch Dermatol","doi-asserted-by":"crossref"}],"short-title":[],"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"update-policy":"https://doi.org/10.1016/elsevier_cm_policy","alternative-id":["S0190962225003044"],"content-domain":{"domain":["clinicalkey.fr","jaad.org","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"original-title":[],"container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2025,6]]},"reference-count":3,"published-online":null,"references-count":3,"short-container-title":["Journal of the American Academy of Dermatology"],"is-referenced-by-count":1},"unpaywall":{"doi":"10.1016/j.jaad.2025.02.028","is_oa":false,"title":"Efficacy and tolerability of low-dose versus high-dose doxycycline in the management of lymphocytic scarring alopecias","updated":"2025-08-17T18:46:03+00:00","published_date":"2025-03-18","best_oa_location":null}},"created_at":"2025-09-19T22:18:26.453Z","updated_at":"2025-09-19T22:40:38.622Z","tags":[{"paper_doi":"10.1016/j.jaad.2025.02.028","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2025.02.028","tag_type":"condition","value":"Lymphocytic Scarring Alopecias","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2025.02.028","tag_type":"generic","value":"doxycycline","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2025.02.028","tag_type":"modality","value":"Tetracycline Antibiotic","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2025.02.028","tag_type":"warning","value":"Only the title and citation were provided; no abstract or results were available to extract specifics.","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2025.02.028","tag_type":"warning","value":"Study design and sample size cannot be determined from the provided information.","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2025.02.028","tag_type":"warning","value":"The specific subtypes included under 'lymphocytic scarring alopecias' are not specified in the provided text.","value_numeric":null}],"summaries":{"what_studied":"Compared low-dose versus high-dose doxycycline for efficacy and tolerability in lymphocytic scarring alopecias."}},{"doi":"10.1001/jamadermatol.2024.6542","pmid":"40042869","title":"Efficacy, Safety, and Tolerability of Oral DFD-29, a Low-Dose Formulation of Minocycline, in Rosacea","journal_title":"JAMA Dermatology","journal_issn":"2168-6068","published_at":"2025-03-05T00:00:00.000Z","url":"https://doi.org/10.1001/jamadermatol.2024.6542","source_score":75,"is_retracted":false,"is_open_access":false,"raw_metadata":{"ooir":{"day":"2025-06-16","doi":"10.1001/jamadermatol.2024.6542","days":"30","issn":"2168-6068","rank":"5","field":"Clinical Medicine","score":"75","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1001/jamadermatol.2024.6542","title":"Efficacy, Safety, and Tolerability of Oral DFD-29, a Low-Dose Formulation of Minocycline, in Rosacea: Two Phase 3 Randomized Clinical Trials.","journal":"JAMA dermatology","methods":"","results":"$31","abstract":"$32","keywords":[],"pubmed_id":"40042869","conclusions":"","publication_date":"2025-03-05T00:00:00"},"crossref":{"DOI":"10.1001/jamadermatol.2024.6542","URL":"https://doi.org/10.1001/jamadermatol.2024.6542","ISSN":["2168-6068"],"link":[{"URL":"https://jamanetwork.com/journals/jamadermatology/articlepdf/2830693/jamadermatology_bhatia_2025_oi_240074_1747728352.5315.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":"499","type":"journal-article","issue":"5","score":1,"title":["Efficacy, Safety, and Tolerability of Oral DFD-29, a Low-Dose Formulation of Minocycline, in Rosacea"],"author":[{"given":"Neal","family":"Bhatia","sequence":"first","affiliation":[{"name":"Therapeutics Clinical Research, San Diego, California"}]},{"given":"James","family":"Del Rosso","sequence":"additional","affiliation":[{"name":"JDR Dermatology Research, Las Vegas, Nevada"}]},{"given":"Linda","family":"Stein Gold","sequence":"additional","affiliation":[{"name":"Henry Ford Health System, Detroit, Michigan"}]},{"given":"Edward","family":"Lain","sequence":"additional","affiliation":[{"name":"Sanova Dermatology, Austin, Texas"}]},{"given":"Zoe Diana","family":"Draelos","sequence":"additional","affiliation":[{"name":"Dermatology Consulting Services, High Point, North Carolina"}]},{"given":"Srinivas","family":"Sidgiddi","sequence":"additional","affiliation":[{"name":"Journey Medical Corporation, Scottsdale, Arizona"}]},{"given":null,"family":null,"sequence":"additional","affiliation":[]},{"given":"Kenneth W.","family":"Dawes","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Sunil S.","family":"Dhawan","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Rosalyn Elizabeth","family":"George","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Cheryl A.","family":"Hull","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Robert S.","family":"Haber","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Jeffrey","family":"Adelglass","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Javier","family":"Alonso-Llamazares","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Mark","family":"Amster","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Francisco L.","family":"Badar","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Sureka","family":"Bollepalli","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Steven A.","family":"Davis","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Oscar","family":"De Valle","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"James Q.","family":"Del Rosso","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Zoe Diana","family":"Draelos","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"David","family":"Fivenson","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"David L.","family":"Fried","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Terry M.","family":"Jones","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Steven E","family":"Kempers","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Francisco A.","family":"Kerdel","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Michael H.","family":"Gold","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Pinkas E.","family":"Lebovits","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Neal D.","family":"Bhatia","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Mark S.","family":"Lee","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Mark A.","family":"McCune","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Steven K.","family":"Grekin","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Walter K.","family":"Nahm","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Jorge L.","family":"Santander","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Stephen M.","family":"Schleicher","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Javier F.","family":"Chang","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Linda Stein","family":"Gold","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Matthew L.","family":"Miller","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Leonardo M.","family":"Allende","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Eddie","family":"Armas","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Megan Poynot","family":"Couvillion","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Jess J.","family":"DeMaria","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Francisco","family":"Flores","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Theresa Greene","family":"Knoepp","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Edward L.","family":"Lain","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Megan B.","family":"Vissing","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Douglas K.","family":"Logan","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Cindy E.","family":"Owen","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Melody Lynn","family":"Stone","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Janet C.","family":"DuBois","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Diane E.","family":"Vargas","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Hector","family":"Wiltz","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Paul Steven","family":"Yamauchi","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Scott T.","family":"Guenthner","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Cheryl","family":"Burgess","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Thomas","family":"Dirschka","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Athanasios","family":"Tsianakas","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Johannes","family":"Niesmann","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Jens","family":"Rossbacher","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Sebastian","family":"Zimmer","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Swarna","family":"Ekanayake-Bohlig","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Rolf","family":"Dominicus","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Oliver","family":"Weirich","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Beate","family":"Schwarz","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Tanja C.","family":"Fischer","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Harald","family":"Brüning","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Beatrice","family":"Gerlach","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]},{"given":"Udo","family":"Amann","sequence":"additional","affiliation":[{"name":"for the MVOR-1 and MVOR-2 Study Investigators"}]}],"issued":{"date-parts":[[2025,5,1]]},"member":"10","prefix":"10.1001","source":"Crossref","volume":"161","created":{"date-time":"2025-03-05T16:02:49Z","timestamp":1741190569000,"date-parts":[[2025,3,5]]},"indexed":{"date-time":"2025-09-03T10:55:32Z","timestamp":1756896932318,"date-parts":[[2025,9,3]]},"subject":[],"abstract":"$33","language":"en","relation":{},"resource":{"primary":{"URL":"https://jamanetwork.com/journals/jamadermatology/fullarticle/2830693"}},"subtitle":["Two Phase 3 Randomized Clinical Trials"],"deposited":{"date-time":"2025-05-21T15:00:31Z","timestamp":1747839631000,"date-parts":[[2025,5,21]]},"issn-type":[{"type":"print","value":"2168-6068"}],"published":{"date-parts":[[2025,5,1]]},"publisher":"American Medical Association (AMA)","reference":[{"DOI":"10.1111/bjd.16481","key":"doi240074r1","year":"2018","issue":"2","author":"Gether","volume":"179","first-page":"282","unstructured":null,"article-title":"Incidence and prevalence of rosacea: a systematic review and meta-analysis.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":null,"key":"doi240074r2","year":"2015","issue":"3","author":"Oge’","volume":"92","first-page":"187","unstructured":null,"article-title":"Rosacea: diagnosis and treatment.","journal-title":"Am Fam Physician","doi-asserted-by":null},{"DOI":"10.1111/bjd.18420","key":"doi240074r3","year":"2020","issue":"5","author":"Schaller","volume":"182","first-page":"1269","unstructured":null,"article-title":"Recommendations for rosacea diagnosis, classification and management: update from the Global Rosacea Consensus 2019 Panel.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":null,"key":"doi240074r4","year":"2015","issue":"4","author":"van Zuuren","volume":null,"first-page":null,"unstructured":null,"article-title":"Interventions for rosacea.","journal-title":"Cochrane Database Syst Rev","doi-asserted-by":null},{"DOI":null,"key":"doi240074r5","year":"2019","issue":"6","author":"Del Rosso","volume":"12","first-page":"17","unstructured":null,"article-title":"Update on the management of rosacea from the American Acne & Rosacea Society (AARS).","journal-title":"J Clin Aesthet Dermatol","doi-asserted-by":null},{"DOI":null,"key":"doi240074r6","year":"2013","issue":"6","author":"Del Rosso","volume":"92","first-page":"277","unstructured":null,"article-title":"Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 2: a status report on topical agents.","journal-title":"Cutis","doi-asserted-by":null},{"DOI":"10.2340/0001555572178179","key":"doi240074r7","year":"1992","issue":"3","author":"Akamatsu","volume":"72","first-page":"178","unstructured":null,"article-title":"Effect of doxycycline on the generation of reactive oxygen species: a possible mechanism of action of acne therapy with doxycycline.","journal-title":"Acta Derm Venereol","doi-asserted-by":"publisher"},{"DOI":"10.1902/jop.2008.080051","key":"doi240074r8","year":"2008","issue":"9","author":"Cazalis","volume":"79","first-page":"1762","unstructured":null,"article-title":"Doxycycline reduces lipopolysaccharide-induced inflammatory mediator secretion in macrophage and ex vivo human whole blood models.","journal-title":"J Periodontol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.phrs.2010.10.004","key":"doi240074r9","year":"2011","issue":"2","author":"Griffin","volume":"63","first-page":"102","unstructured":null,"article-title":"Tetracycline compounds with non-antimicrobial organ protective properties: possible mechanisms of action.","journal-title":"Pharmacol Res","doi-asserted-by":"publisher"},{"DOI":"10.4049/jimmunol.176.1.567","key":"doi240074r10","year":"2006","issue":"1","author":"Hoyt","volume":"176","first-page":"567","unstructured":null,"article-title":"Doxycycline modulates nitric oxide production in murine lung epithelial cells.","journal-title":"J Immunol","doi-asserted-by":"publisher"},{"DOI":"10.1128/AAC.01540-08","key":"doi240074r11","year":"2009","issue":"5","author":"Ishikawa","volume":"53","first-page":"1760","unstructured":null,"article-title":"Tetracyclines modulate protease-activated receptor 2-mediated proinflammatory reactions in epidermal keratinocytes.","journal-title":"Antimicrob Agents Chemother","doi-asserted-by":"publisher"},{"DOI":null,"key":"doi240074r12","year":"1998","issue":"9","author":"Pruzanski","volume":"25","first-page":"1807","unstructured":null,"article-title":"Chemically modified non-antimicrobial tetracyclines inhibit activity of phospholipases A2.","journal-title":"J Rheumatol","doi-asserted-by":null},{"DOI":"10.2174/0929867013373598","key":"doi240074r13","year":"2001","issue":"3","author":"Ryan","volume":"8","first-page":"305","unstructured":null,"article-title":"Excessive matrix metalloproteinase activity in diabetes: inhibition by tetracycline analogues with zinc reactivity.","journal-title":"Curr Med Chem","doi-asserted-by":"publisher"},{"DOI":"10.1016/0266-4356(94)90137-6","key":"doi240074r14","year":"1994","issue":"2","author":"Ueyama","volume":"32","first-page":"96","unstructured":null,"article-title":"Effects of antibiotics on human polymorphonuclear leukocyte chemotaxis in vitro.","journal-title":"Br J Oral Maxillofac Surg","doi-asserted-by":"publisher"},{"DOI":null,"key":"doi240074r16","year":"2006","issue":"3","author":"Del Rosso","volume":"77","first-page":"153","unstructured":null,"article-title":"Clinical significance of brand versus generic formulations: focus on oral minocycline.","journal-title":"Cutis","doi-asserted-by":null},{"DOI":"10.1002/14651858.CD002086.pub2","key":"doi240074r17","year":"2012","issue":"8","author":"Garner","volume":"2012","first-page":null,"unstructured":null,"article-title":"Minocycline for acne vulgaris: efficacy and safety.","journal-title":"Cochrane Database Syst Rev","doi-asserted-by":"publisher"},{"DOI":"10.3390/antibiotics10070757","key":"doi240074r18","year":"2021","issue":"7","author":"Martins","volume":"10","first-page":"757","unstructured":null,"article-title":"A review of systemic minocycline side effects and topical minocycline as a safer alternative for treating acne and rosacea.","journal-title":"Antibiotics (Basel)","doi-asserted-by":"publisher"},{"DOI":null,"key":"doi240074r20","year":"2021","issue":"12","author":"Tsianakas","volume":"14","first-page":"16","unstructured":null,"article-title":"Minocycline extended-release comparison with doxycycline for the treatment of rosacea: a randomized, head-to-head, clinical trial.","journal-title":"J Clin Aesthet Dermatol","doi-asserted-by":null},{"DOI":"10.1001/jama.2013.281053","key":"doi240074r21","year":"2013","issue":"20","author":"World Medical Association","volume":"310","first-page":"2191","unstructured":null,"article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","journal-title":"JAMA","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2014.05.044","key":"doi240074r22","year":"2014","issue":"4","author":"Tan","volume":"71","first-page":"760","unstructured":null,"article-title":"Reliability of Clinician Erythema Assessment grading scale.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2006.11.021","key":"doi240074r23","year":"2007","issue":"5","author":"Del Rosso","volume":"56","first-page":"791","unstructured":null,"article-title":"Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2015.12.037","key":"doi240074r24","year":"2016","issue":"5","author":"Zaenglein","volume":"74","first-page":"945","unstructured":null,"article-title":"Guidelines of care for the management of acne vulgaris.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":null,"key":"doi240074r25","year":"2014","issue":"3","author":"Fiscus","volume":"4","first-page":null,"unstructured":null,"article-title":"Minocycline-induced hyperpigmentation.","journal-title":"J Community Hosp Intern Med Perspect","doi-asserted-by":null},{"DOI":"10.1159/000017852","key":"doi240074r26","year":"1998","issue":"1","author":"Chosidow","volume":"196","first-page":"162","unstructured":null,"article-title":"Comedonal diffusion of minocycline in acne.","journal-title":"Dermatology","doi-asserted-by":"publisher"},{"DOI":null,"key":"doi240074r27","year":"2021","issue":"8","author":"Del Rosso","volume":"14","first-page":"14","unstructured":null,"article-title":"Nonantibiotic properties of tetracyclines in rosacea and their clinical implications.","journal-title":"J Clin Aesthet Dermatol","doi-asserted-by":null},{"DOI":"10.1111/bph.12139","key":"doi240074r28","year":"2013","issue":"2","author":"Garrido-Mesa","volume":"169","first-page":"337","unstructured":null,"article-title":"Minocycline: far beyond an antibiotic.","journal-title":"Br J Pharmacol","doi-asserted-by":"publisher"},{"DOI":"10.1007/s00011-016-0999-x","key":"doi240074r29","year":"2017","issue":"2","author":"Parenti","volume":"66","first-page":"107","unstructured":null,"article-title":"Minocycline affects human neutrophil respiratory burst and transendothelial migration.","journal-title":"Inflamm Res","doi-asserted-by":"publisher"},{"DOI":"10.1093/jac/48.suppl_1.5","key":"doi240074r30","year":"2001","issue":null,"author":"Andrews","volume":"48","first-page":"5","unstructured":null,"article-title":"Determination of minimum inhibitory concentrations.","journal-title":"J Antimicrob Chemother","doi-asserted-by":"publisher"},{"DOI":null,"key":"doi240074r31","year":"2007","issue":"6","author":"Fowler","volume":"6","first-page":"641","unstructured":null,"article-title":"Combined effect of anti-inflammatory dose doxycycline (40-mg doxycycline, usp monohydrate controlled-release capsules) and metronidazole topical gel 1% in the treatment of rosacea.","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":"10.1046/j.1365-2133.2001.03956.x","key":"doi240074r32","year":"2001","issue":"2","author":"Ross","volume":"144","first-page":"339","unstructured":null,"article-title":"Phenotypic and genotypic characterization of antibiotic-resistant Propionibacterium acnes isolated from acne patients attending dermatology clinics in Europe, the U.S.A., Japan and Australia.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1086/598510","key":"doi240074r33","year":"2009","issue":"10","author":"Schwartz","volume":"48","first-page":"1483","unstructured":null,"article-title":"Doxycycline, not minocycline, induces its own resistance in multidrug-resistant, community-associated methicillin-resistant Staphylococcus aureus clone USA300.","journal-title":"Clin Infect Dis","doi-asserted-by":"publisher"},{"DOI":"10.1007/s12325-016-0380-z","key":"doi240074r34","year":"2016","issue":"9","author":"Steinhoff","volume":"33","first-page":"1481","unstructured":null,"article-title":"Topical ivermectin 10 mg/g and oral doxycycline 40 mg modified-release: current evidence on the complementary use of anti-inflammatory rosacea treatments.","journal-title":"Adv Ther","doi-asserted-by":"publisher"},{"DOI":"10.1126/scitranslmed.abd8077","key":"doi240074r36","year":"2021","issue":"625","author":"Jo","volume":"13","first-page":null,"unstructured":null,"article-title":"Alterations of human skin microbiome and expansion of antimicrobial resistance after systemic antibiotics.","journal-title":"Sci Transl Med","doi-asserted-by":"publisher"},{"DOI":"10.1902/jop.2000.71.9.1472","key":"doi240074r37","year":"2000","issue":"9","author":"Thomas","volume":"71","first-page":"1472","unstructured":null,"article-title":"Long-term use of subantimicrobial dose doxycycline does not lead to changes in antimicrobial susceptibility.","journal-title":"J Periodontol","doi-asserted-by":"publisher"},{"DOI":null,"key":"doi240074r35","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"doi240074r15","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Oracea. Prescribing information. Galderma Laboratories; 2022. Accessed February 6, 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/050805s002lbl.pdf","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"doi240074r19","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Minocin. Prescribing information. Triax Pharmaceuticals; 2010. Accessed February 5, 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/050649023lbl.pdf","article-title":null,"journal-title":null,"doi-asserted-by":null}],"short-title":[],"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5,1]]}},"content-domain":{"domain":[],"crossmark-restriction":false},"original-title":[],"container-title":["JAMA Dermatology"],"published-print":{"date-parts":[[2025,5,1]]},"reference-count":37,"published-online":null,"references-count":37,"short-container-title":["JAMA Dermatol"],"is-referenced-by-count":1},"unpaywall":{"doi":"10.1001/jamadermatol.2024.6542","is_oa":false,"title":"Efficacy, Safety, and Tolerability of Oral DFD-29, a Low-Dose Formulation of Minocycline, in Rosacea","updated":"2025-08-04T14:10:34+00:00","published_date":"2025-03-05","best_oa_location":null}},"created_at":"2025-09-19T18:40:43.237Z","updated_at":"2025-09-19T18:49:32.880Z","tags":[{"paper_doi":"10.1001/jamadermatol.2024.6542","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.6542","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.6542","tag_type":"condition","value":"Papulopustular Rosacea","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.6542","tag_type":"generic","value":"doxycycline","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.6542","tag_type":"generic","value":"minocycline","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.6542","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.6542","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.6542","tag_type":"modality","value":"Tetracycline Antibiotic","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.6542","tag_type":"sample_size","value":"n=653","value_numeric":653},{"paper_doi":"10.1001/jamadermatol.2024.6542","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.6542","tag_type":"study_design","value":"Randomized Controlled Trial","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.6542","tag_type":"warning","value":"Absolute IGA success rates and baseline lesion counts are not reported; only treatment differences and least-squares mean changes are provided.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.6542","tag_type":"warning","value":"Findings are pooled across two separate phase 3 RCTs when summarizing effects.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.6542","tag_type":"warning","value":"Outcomes are reported over 16 weeks; longer-term efficacy and safety are not described in the abstract.","value_numeric":null}],"summaries":{"what_studied":"Two phase 3, double-blind randomized trials (MVOR-1 and MVOR-2) tested oral DFD-29 (minocycline HCl) 40 mg once daily vs doxycycline 40 mg and placebo for 16 weeks in adults with moderate to severe papulopustular rosacea.","key_result":"DFD-29 increased IGA treatment success vs placebo by 32.9% (95% CI, 19.6–46.2) and 34.1% (21.3–46.8) and vs doxycycline by 18.0% (5.0–31.1) and 28.3% (17.4–39.3), all P≤.01. It reduced total inflammatory lesions vs placebo by LS mean −9.2 and −6.8 and vs doxycycline by −4.7 and −3.5; adverse events occurred in 32/121 (26.4%) and 51/122 (41.8%) on DFD-29 vs 25/116 (21.6%) and 40/121 (33.1%) on doxycycline and 27/76 (35.5%) and 30/82 (36.6%) on placebo.","practice_takeaway":"In adults with moderate to severe papulopustular rosacea, 16 weeks of DFD-29 40 mg daily outperformed doxycycline 40 mg and placebo on IGA success and lesion reduction, with no excess adverse events in these trials."}},{"doi":"10.1016/j.jaad.2023.12.017","pmid":"38300170","title":"Guidelines of care for the management of acne vulgaris","journal_title":"Journal of the American Academy of Dermatology","journal_issn":"0190-9622","published_at":"2024-02-01T00:00:00.000Z","url":"https://doi.org/10.1016/j.jaad.2023.12.017","source_score":374,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2024-04-16","doi":"10.1016/j.jaad.2023.12.017","days":"30","issn":"0190-9622","rank":"1","field":"Clinical Medicine","score":"374","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1016/j.jaad.2023.12.017","title":"Guidelines of care for the management of acne vulgaris.","journal":"Journal of the American Academy of Dermatology","methods":"","results":"This guideline presents 18 evidence-based recommendations and 5 good practice statements. Strong recommendations are made for benzoyl peroxide, topical retinoids, topical antibiotics, and oral doxycycline. Oral isotretinoin is strongly recommended for acne that is severe, causing psychosocial burden or scarring, or failing standard oral or topical therapy. Conditional recommendations are made for topical clascoterone, salicylic acid, and azelaic acid, as well as for oral minocycline, sarecycline, combined oral contraceptive pills, and spironolactone. Combining topical therapies with multiple mechanisms of action, limiting systemic antibiotic use, combining systemic antibiotics with topical therapies, and adding intralesional corticosteroid injections for larger acne lesions are recommended as good practice statements.","abstract":"$34","keywords":["Acne","Cutibacterium acnes","acne vulgaris","adapalene","antiandrogens","antibiotics","azelaic acid","azithromycin","benzoyl peroxide","clascoterone","clindamycin","contraceptives","corticosteroids","diet and acne","doxycycline","erythromycin","grading and classification of acne","guidelines","hormonal therapy","isotretinoin","light therapies","microbiological and endocrine testing","minocycline","retinoids","salicylic acid","sarecycline","spironolactone","tazarotene","treatment","tretinoin","trifarotene"],"pubmed_id":"38300170","conclusions":"","publication_date":"2024-02-01T00:00:00"},"crossref":{"DOI":"10.1016/j.jaad.2023.12.017","URL":"https://doi.org/10.1016/j.jaad.2023.12.017","ISSN":["0190-9622"],"link":[{"URL":"https://api.elsevier.com/content/article/PII:S0190962223033893?httpAccept=text/xml","content-type":"text/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https://api.elsevier.com/content/article/PII:S0190962223033893?httpAccept=text/plain","content-type":"text/plain","content-version":"vor","intended-application":"text-mining"}],"page":"1006.e1-1006.e30","type":"journal-article","issue":"5","score":1,"title":["Guidelines of care for the management of acne vulgaris"],"author":[{"given":"Rachel V.","family":"Reynolds","sequence":"first","affiliation":[]},{"given":"Howa","family":"Yeung","sequence":"additional","affiliation":[]},{"given":"Carol E.","family":"Cheng","sequence":"additional","affiliation":[]},{"given":"Fran","family":"Cook-Bolden","sequence":"additional","affiliation":[]},{"given":"Seemal R.","family":"Desai","sequence":"additional","affiliation":[]},{"given":"Kelly M.","family":"Druby","sequence":"additional","affiliation":[]},{"given":"Esther E.","family":"Freeman","sequence":"additional","affiliation":[]},{"given":"Jonette E.","family":"Keri","sequence":"additional","affiliation":[]},{"given":"Linda F.","family":"Stein Gold","sequence":"additional","affiliation":[]},{"given":"Jerry K.L.","family":"Tan","sequence":"additional","affiliation":[]},{"given":"Megha M.","family":"Tollefson","sequence":"additional","affiliation":[]},{"given":"Jonathan S.","family":"Weiss","sequence":"additional","affiliation":[]},{"given":"Peggy A.","family":"Wu","sequence":"additional","affiliation":[]},{"given":"Andrea L.","family":"Zaenglein","sequence":"additional","affiliation":[]},{"given":"Jung Min","family":"Han","sequence":"additional","affiliation":[]},{"given":"John S.","family":"Barbieri","sequence":"additional","affiliation":[]}],"funder":[{"id":[{"id":"10.13039/100001934","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/100001934","name":"American Academy of Dermatology","doi-asserted-by":"publisher"}],"issued":{"date-parts":[[2024,5]]},"member":"78","prefix":"10.1016","source":"Crossref","volume":"90","created":{"date-time":"2024-01-30T08:25:55Z","timestamp":1706603155000,"date-parts":[[2024,1,30]]},"indexed":{"date-time":"2025-09-20T07:51:25Z","timestamp":1758354685137,"date-parts":[[2025,9,20]]},"license":[{"URL":"https://www.elsevier.com/tdm/userlicense/1.0/","start":{"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000,"date-parts":[[2024,5,1]]},"delay-in-days":0,"content-version":"tdm"},{"URL":"https://www.elsevier.com/legal/tdmrep-license","start":{"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000,"date-parts":[[2024,5,1]]},"delay-in-days":0,"content-version":"tdm"}],"subject":[],"abstract":null,"language":"en","relation":{},"resource":{"primary":{"URL":"https://linkinghub.elsevier.com/retrieve/pii/S0190962223033893"}},"subtitle":[],"assertion":[{"name":"publisher","label":"This article is maintained by","value":"Elsevier"},{"name":"articletitle","label":"Article Title","value":"Guidelines of care for the management of acne vulgaris"},{"name":"journaltitle","label":"Journal Title","value":"Journal of the American Academy of Dermatology"},{"name":"articlelink","label":"CrossRef DOI link to publisher maintained version","value":"https://doi.org/10.1016/j.jaad.2023.12.017"},{"name":"content_type","label":"Content Type","value":"article"},{"name":"copyright","label":"Copyright","value":"© 2024 by the American Academy of Dermatology, Inc."}],"deposited":{"date-time":"2024-06-05T21:02:34Z","timestamp":1717621354000,"date-parts":[[2024,6,5]]},"issn-type":[{"type":"print","value":"0190-9622"}],"published":{"date-parts":[[2024,5]]},"publisher":"Elsevier BV","reference":[{"DOI":"10.1016/j.jaad.2016.12.043","key":"10.1016/j.jaad.2023.12.017_bib1","year":"2017","issue":null,"author":"Lim","volume":"76","first-page":"958","unstructured":null,"article-title":"The burden of skin disease in the United States","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1111/bjd.20882","key":"10.1016/j.jaad.2023.12.017_bib2","year":"2022","issue":null,"author":"Chen","volume":"186","first-page":"673","unstructured":null,"article-title":"Magnitude and temporal trend of acne vulgaris burden in 204 countries and territories from 1990 to 2019: an analysis from the global burden of disease study 2019","journal-title":"Br J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaad.2015.12.037","key":"10.1016/j.jaad.2023.12.017_bib3","year":"2016","issue":null,"author":"Zaenglein","volume":"74","first-page":"945","unstructured":null,"article-title":"Guidelines of care for the management of acne vulgaris","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1542/peds.2013-0490B","key":"10.1016/j.jaad.2023.12.017_bib4","year":"2013","issue":"Suppl 3","author":"Eichenfield","volume":"131","first-page":"S163","unstructured":null,"article-title":"Evidence-based recommendations for the diagnosis and treatment of pediatric acne","journal-title":"Pediatrics","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jclinepi.2012.03.013","key":"10.1016/j.jaad.2023.12.017_bib5","year":"2013","issue":null,"author":"Andrews","volume":"66","first-page":"719","unstructured":null,"article-title":"GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations","journal-title":"J Clin Epidemiol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jclinepi.2013.02.003","key":"10.1016/j.jaad.2023.12.017_bib6","year":"2013","issue":null,"author":"Andrews","volume":"66","first-page":"726","unstructured":null,"article-title":"GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation's direction and strength","journal-title":"J Clin Epidemiol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jclinepi.2016.07.006","key":"10.1016/j.jaad.2023.12.017_bib7","year":"2016","issue":null,"author":"Guyatt","volume":"80","first-page":"3","unstructured":null,"article-title":"Guideline panels should seldom make good practice statements: guidance from the GRADE Working Group","journal-title":"J Clin Epidemiol","doi-asserted-by":"crossref"},{"DOI":"10.1001/jama.2021.17633","key":"10.1016/j.jaad.2023.12.017_bib8","year":"2021","issue":null,"author":"Eichenfield","volume":"326","first-page":"2055","unstructured":null,"article-title":"Management of acne vulgaris: a review","journal-title":"JAMA","doi-asserted-by":"crossref"},{"DOI":"10.1038/jid.2013.446","key":"10.1016/j.jaad.2023.12.017_bib9","year":"2014","issue":null,"author":"Hay","volume":"134","first-page":"1527","unstructured":null,"article-title":"The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions","journal-title":"J Invest Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1111/bjd.12149","key":"10.1016/j.jaad.2023.12.017_bib10","year":"2013","issue":null,"author":"Bhate","volume":"168","first-page":"474","unstructured":null,"article-title":"Epidemiology of acne vulgaris","journal-title":"Br J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1001/jamadermatol.2016.5538","key":"10.1016/j.jaad.2023.12.017_bib11","year":"2017","issue":null,"author":"Karimkhani","volume":"153","first-page":"406","unstructured":null,"article-title":"Global skin disease morbidity and mortality: an update from the global burden of disease study 2013","journal-title":"JAMA Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0190-9622(98)70442-6","key":"10.1016/j.jaad.2023.12.017_bib12","year":"1998","issue":null,"author":"White","volume":"39","first-page":"S34","unstructured":null,"article-title":"Recent findings in the epidemiologic evidence, classification, and subtypes of acne vulgaris","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1007/s13555-018-0224-7","key":"10.1016/j.jaad.2023.12.017_bib13","year":"2018","issue":null,"author":"Fabbrocini","volume":"8","first-page":"85","unstructured":null,"article-title":"A qualitative investigation of the impact of acne on health-related quality of life (HRQL): development of a conceptual model","journal-title":"Dermatol Ther","doi-asserted-by":"crossref"},{"DOI":"10.1001/jamadermatol.2021.2185","key":"10.1016/j.jaad.2023.12.017_bib14","year":"2021","issue":null,"author":"Barbieri","volume":"157","first-page":"1040","unstructured":null,"article-title":"Patient perspectives on the lived experience of acne and its treatment among adult women with acne: a qualitative study","journal-title":"JAMA Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1046/j.1365-2133.1999.02768.x","key":"10.1016/j.jaad.2023.12.017_bib15","year":"1999","issue":null,"author":"Mallon","volume":"140","first-page":"672","unstructured":null,"article-title":"The quality of life in acne: a comparison with general medical conditions using generic questionnaires","journal-title":"Br J Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib16","year":"2014","issue":null,"author":"Cresce","volume":"13","first-page":"692","unstructured":null,"article-title":"The quality of life impact of acne and rosacea compared to other major medical conditions","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":"10.1046/j.1365-2133.1998.02511.x","key":"10.1016/j.jaad.2023.12.017_bib17","year":"1998","issue":null,"author":"Gupta","volume":"139","first-page":"846","unstructured":null,"article-title":"Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis","journal-title":"Br J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1111/j.1471-6712.2007.00547.x","key":"10.1016/j.jaad.2023.12.017_bib18","year":"2008","issue":null,"author":"Magin","volume":"22","first-page":"430","unstructured":null,"article-title":"Experiences of appearance-related teasing and bullying in skin diseases and their psychological sequelae: results of a qualitative study","journal-title":"Scand J Caring Sci","doi-asserted-by":"crossref"},{"DOI":"10.1186/1751-0759-5-11","key":"10.1016/j.jaad.2023.12.017_bib19","year":"2011","issue":null,"author":"Ritvo","volume":"5","first-page":"11","unstructured":null,"article-title":"Psychosocial judgements and perceptions of adolescents with acne vulgaris: a blinded, controlled comparison of adult and peer evaluations","journal-title":"Biopsychosoc Med","doi-asserted-by":"crossref"},{"DOI":"10.1111/j.1440-1754.2006.00979.x","key":"10.1016/j.jaad.2023.12.017_bib20","year":"2006","issue":null,"author":"Purvis","volume":"42","first-page":"793","unstructured":null,"article-title":"Acne, anxiety, depression and suicide in teenagers: a cross-sectional survey of New Zealand secondary school students","journal-title":"J Paediatr Child Health","doi-asserted-by":"crossref"},{"DOI":"10.1038/s41598-020-62715-3","key":"10.1016/j.jaad.2023.12.017_bib21","year":"2020","issue":null,"author":"Heng","volume":"10","first-page":"5754","unstructured":null,"article-title":"Systematic review of the epidemiology of acne vulgaris","journal-title":"Sci Rep","doi-asserted-by":"crossref"},{"DOI":"10.1111/jebm.12249","key":"10.1016/j.jaad.2023.12.017_bib22","year":"2017","issue":null,"author":"Layton","volume":"10","first-page":"163","unstructured":null,"article-title":"Prioritizing treatment outcomes: how people with acne vulgaris decide if their treatment is working","journal-title":"J Evid Based Med","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib23","year":"2005","issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.3109/09546639809160698","key":"10.1016/j.jaad.2023.12.017_bib24","year":"1998","issue":null,"author":"O'Brien","volume":"9","first-page":"215","unstructured":null,"article-title":"The Leeds revised acne grading system","journal-title":"J Dermatol Treat","doi-asserted-by":"crossref"},{"DOI":"10.1046/j.1365-4362.1997.00099.x","key":"10.1016/j.jaad.2023.12.017_bib25","year":"1997","issue":null,"author":"Doshi","volume":"36","first-page":"416","unstructured":null,"article-title":"A comparison of current acne grading systems and proposal of a novel system","journal-title":"Int J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1111/j.1468-3083.2010.03685.x","key":"10.1016/j.jaad.2023.12.017_bib26","year":"2011","issue":null,"author":"Dreno","volume":"25","first-page":"43","unstructured":null,"article-title":"Development and evaluation of a global acne severity scale (GEA scale) suitable for France and Europe","journal-title":"J Eur Acad Dermatol Venereol","doi-asserted-by":"crossref"},{"DOI":"10.2310/7750.2007.00037","key":"10.1016/j.jaad.2023.12.017_bib27","year":"2007","issue":null,"author":"Tan","volume":"11","first-page":"211","unstructured":null,"article-title":"Development and validation of a comprehensive acne severity scale","journal-title":"J Cutan Med Surg","doi-asserted-by":"crossref"},{"DOI":"10.1111/pde.13262","key":"10.1016/j.jaad.2023.12.017_bib28","year":"2017","issue":null,"author":"Patel","volume":"34","first-page":"656","unstructured":null,"article-title":"The patient-centered acne severity scale study","journal-title":"Pediatr Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1001/jamadermatol.2019.4668","key":"10.1016/j.jaad.2023.12.017_bib29","year":"2020","issue":null,"author":"Bernardis","volume":"156","first-page":"296","unstructured":null,"article-title":"Development and initial validation of a multidimensional acne global grading system integrating primary lesions and secondary changes","journal-title":"JAMA Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1111/1346-8138.15613","key":"10.1016/j.jaad.2023.12.017_bib30","year":"2021","issue":null,"author":"Cho","volume":"48","first-page":"42","unstructured":null,"article-title":"Analysis of trends and status of physician-based evaluation methods in acne vulgaris from 2000 to 2019","journal-title":"J Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib31","year":"2016","issue":null,"author":"Stein Gold","volume":"15","first-page":"79","unstructured":null,"article-title":"Evolution of acne assessments and impact on acne medications: an evolving, imperfect paradigm","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":"10.1016/j.jaad.2013.07.029","key":"10.1016/j.jaad.2023.12.017_bib32","year":"2013","issue":null,"author":"Tan","volume":"69","first-page":"754","unstructured":null,"article-title":"Evaluation of essential clinical components and features of current acne global grading scales","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaad.2011.09.005","key":"10.1016/j.jaad.2023.12.017_bib33","year":"2012","issue":null,"author":"Tan","volume":"67","first-page":"187","unstructured":null,"article-title":"Acne severity grading: determining essential clinical components and features using a Delphi consensus","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaad.2018.09.017","key":"10.1016/j.jaad.2023.12.017_bib34","year":"2019","issue":null,"author":"Gottlieb","volume":"80","first-page":"823","unstructured":null,"article-title":"A provider global assessment quality measure for clinical practice for inflammatory skin disorders","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.clindermatol.2016.10.006","key":"10.1016/j.jaad.2023.12.017_bib35","year":"2017","issue":null,"author":"Becker","volume":"35","first-page":"147","unstructured":null,"article-title":"Objective assessment of acne","journal-title":"Clin Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1111/jdv.14585","key":"10.1016/j.jaad.2023.12.017_bib36","year":"2018","issue":null,"author":"Chernyshov","volume":"32","first-page":"194","unstructured":null,"article-title":"Quality of life measurement in acne. Position paper of the European Academy of Dermatology and Venereology task forces on quality of life and patient oriented outcomes and acne, rosacea and hidradenitis suppurativa","journal-title":"J Eur Acad Dermatol Venereol","doi-asserted-by":"crossref"},{"DOI":"10.1007/s40257-019-00438-6","key":"10.1016/j.jaad.2023.12.017_bib37","year":"2019","issue":null,"author":"Marron","volume":"20","first-page":"527","unstructured":null,"article-title":"Quality-of-Life research in acne vulgaris: current status and future directions","journal-title":"Am J Clin Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1001/jamadermatol.2022.2260","key":"10.1016/j.jaad.2023.12.017_bib38","year":"2022","issue":null,"author":"Hopkins","volume":"158","first-page":"900","unstructured":null,"article-title":"Patient-reported outcome measures for health-related quality of life in patients with acne vulgaris: a systematic review of measure development and measurement properties","journal-title":"JAMA Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1038/jid.2013.21","key":"10.1016/j.jaad.2023.12.017_bib39","year":"2013","issue":null,"author":"Fitz-Gibbon","volume":"133","first-page":"2152","unstructured":null,"article-title":"Propionibacterium acnes strain populations in the human skin microbiome associated with acne","journal-title":"J Invest Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib40","year":"2010","issue":null,"author":"Miura","volume":"57","first-page":"65","unstructured":null,"article-title":"Quantitative PCR of Propionibacterium acnes DNA in samples aspirated from sebaceous follicles on the normal skin of subjects with or without acne","journal-title":"J Med Dent Sci","doi-asserted-by":null},{"DOI":"10.1111/1346-8138.13245","key":"10.1016/j.jaad.2023.12.017_bib41","year":"2016","issue":null,"author":"Akaza","volume":"43","first-page":"906","unstructured":null,"article-title":"Microorganisms inhabiting follicular contents of facial acne are not only Propionibacterium but also Malassezia spp","journal-title":"J Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib42","year":"2020","issue":null,"author":"Jusuf","volume":"13","first-page":"773","unstructured":null,"article-title":"Differences of microbiomes found in non-inflammatory and inflammatory lesions of acne vulgaris","journal-title":"Clin Cosmet Investig Dermatol","doi-asserted-by":null},{"DOI":"10.1111/exd.13296","key":"10.1016/j.jaad.2023.12.017_bib43","year":"2017","issue":null,"author":"Dreno","volume":"26","first-page":"798","unstructured":null,"article-title":"Skin microbiome and acne vulgaris: staphylococcus, a new actor in acne","journal-title":"Exp Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1007/s12275-021-0647-1","key":"10.1016/j.jaad.2023.12.017_bib44","year":"2021","issue":null,"author":"Kim","volume":"59","first-page":"369","unstructured":null,"article-title":"Inferences in microbial structural signatures of acne microbiome and mycobiome","journal-title":"J Microbiol","doi-asserted-by":"crossref"},{"DOI":"10.1159/000356777","key":"10.1016/j.jaad.2023.12.017_bib45","year":"2014","issue":null,"author":"Numata","volume":"228","first-page":"86","unstructured":null,"article-title":"Analysis of facial skin-resident microbiota in Japanese acne patients","journal-title":"Dermatology","doi-asserted-by":"crossref"},{"DOI":"10.1111/j.1346-8138.2006.00206.x","key":"10.1016/j.jaad.2023.12.017_bib46","year":"2006","issue":null,"author":"Ergin","volume":"33","first-page":"899","unstructured":null,"article-title":"Nasal antibiotic-resistant Propionibacterium acnes carriage in acne vulgaris patients in Turkey","journal-title":"J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1111/j.1365-4632.2011.05371.x","key":"10.1016/j.jaad.2023.12.017_bib47","year":"2013","issue":null,"author":"Schafer","volume":"52","first-page":"418","unstructured":null,"article-title":"Antimicrobial susceptibility and genetic characteristics of Propionibacterium acnes isolated from patients with acne","journal-title":"Int J Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib48","year":"2018","issue":null,"author":"Franik","volume":"22","first-page":"4411","unstructured":null,"article-title":"Hormonal and metabolic aspects of acne vulgaris in women with polycystic ovary syndrome","journal-title":"Eur Rev Med Pharmacol Sci","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib49","year":"2016","issue":null,"author":"Kiayani","volume":"28","first-page":"357","unstructured":null,"article-title":"Association of serum testosterone and sex hormone binding globulin levels in females with acne based on its severity","journal-title":"J Ayub Med Coll Abbottabad","doi-asserted-by":null},{"DOI":"10.1210/jc.2018-00241","key":"10.1016/j.jaad.2023.12.017_bib50","year":"2018","issue":null,"author":"Martin","volume":"103","first-page":"1233","unstructured":null,"article-title":"Evaluation and treatment of hirsutism in premenopausal women: an endocrine society clinical practice guideline","journal-title":"J Clin Endocrinol Metab","doi-asserted-by":"crossref"},{"DOI":"10.1111/j.1365-4632.2007.03411.x","key":"10.1016/j.jaad.2023.12.017_bib51","year":"2007","issue":null,"author":"Seirafi","volume":"46","first-page":"1188","unstructured":null,"article-title":"Assessment of androgens in women with adult-onset acne","journal-title":"Int J Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib52","year":"1990","issue":null,"author":"Schmidt","volume":"24","first-page":"457","unstructured":null,"article-title":"Endocrine parameters in acne vulgaris","journal-title":"Endocrinol Exp","doi-asserted-by":null},{"DOI":"10.1111/1523-1747.ep12539043","key":"10.1016/j.jaad.2023.12.017_bib53","year":"1983","issue":null,"author":"Lucky","volume":"81","first-page":"70","unstructured":null,"article-title":"Plasma androgens in women with acne vulgaris","journal-title":"J Invest Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1111/j.1346-8138.1997.tb02778.x","key":"10.1016/j.jaad.2023.12.017_bib54","year":"1997","issue":null,"author":"Timpatanapong","volume":"24","first-page":"223","unstructured":null,"article-title":"Hormonal profiles and prevalence of polycystic ovary syndrome in women with acne","journal-title":"J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.clinbiochem.2010.09.010","key":"10.1016/j.jaad.2023.12.017_bib55","year":"2010","issue":null,"author":"Arora","volume":"43","first-page":"1415","unstructured":null,"article-title":"The relationship of lipid profile and menstrual cycle with acne vulgaris","journal-title":"Clin Biochem","doi-asserted-by":"crossref"},{"DOI":"10.1590/S0100-879X2009000600005","key":"10.1016/j.jaad.2023.12.017_bib56","year":"2009","issue":null,"author":"Abulnaja","volume":"42","first-page":"501","unstructured":null,"article-title":"Changes in the hormone and lipid profile of obese adolescent Saudi females with acne vulgaris","journal-title":"Braz J Med Biol Res","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib57","year":"2012","issue":null,"author":"Saleh","volume":"33","first-page":"1196","unstructured":null,"article-title":"Role of growth hormone and insulin-like growth factor-I in hyperandrogenism and the severity of acne vulgaris in young males","journal-title":"Saudi Med J","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib58","year":"2018","issue":"10","author":"Tyring","volume":"17","first-page":"1084","unstructured":null,"article-title":"Novel tretinoin 0.05% lotion for the once-daily treatment of moderate-to-severe acne vulgaris: assessment of efficacy and safety in patients aged 9 years and older","journal-title":"J Drugs Dermatol JDD","doi-asserted-by":null},{"DOI":"10.1016/j.jaad.2004.10.879","key":"10.1016/j.jaad.2023.12.017_bib59","year":"2006","issue":null,"author":"Thiboutot","volume":"54","first-page":"242","unstructured":null,"article-title":"Adapalene gel 0.3% for the treatment of acne vulgaris: a multicenter, randomized, double-blind, controlled, phase III trial","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib60","year":"1999","issue":null,"author":"Shalita","volume":"63","first-page":"349","unstructured":null,"article-title":"Tazarotene gel is safe and effective in the treatment of acne vulgaris: a multicenter, double-blind, vehicle-controlled study","journal-title":"Cutis","doi-asserted-by":null},{"DOI":"10.36849/JDD.2020.3977","key":"10.1016/j.jaad.2023.12.017_bib61","year":"2020","issue":null,"author":"Tanghetti","volume":"19","first-page":"70","unstructured":null,"article-title":"Tazarotene 0.045% lotion for once-daily treatment of moderate-to-severe acne vulgaris: results from two phase 3 trials","journal-title":"J Drugs Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaad.2019.02.044","key":"10.1016/j.jaad.2023.12.017_bib62","year":"2019","issue":"6","author":"Tan","volume":"80","first-page":"1691","unstructured":null,"article-title":"Randomized phase 3 evaluation of trifarotene 50 mug/g cream treatment of moderate facial and truncal acne","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib63","year":"2020","issue":"6","author":"Webster","volume":"18","first-page":"343","unstructured":null,"article-title":"Microencapsulated benzoyl peroxide and tretinoin for the treatment of acne vulgaris: results from a phase 2 multicenter, double-blind, randomized, vehicle-controlled study","journal-title":"Skinmed","doi-asserted-by":null},{"DOI":"10.1111/j.1365-2133.2009.09209.x","key":"10.1016/j.jaad.2023.12.017_bib64","year":"2009","issue":null,"author":"Gollnick","volume":"161","first-page":"1180","unstructured":null,"article-title":"Adapalene-benzoyl peroxide, a unique fixed-dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double-blind, controlled study in 1670 patients","journal-title":"Br J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1111/1346-8138.12580","key":"10.1016/j.jaad.2023.12.017_bib65","year":"2014","issue":"9","author":"Kawashima","volume":"41","first-page":"795","unstructured":null,"article-title":"Is benzoyl peroxide 3% topical gel effective and safe in the treatment of acne vulgaris in Japanese patients? A multicenter, randomized, double-blind, vehicle-controlled, parallel-group study","journal-title":"J Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib66","year":"2011","issue":null,"author":"Eichenfield","volume":"10","first-page":"1382","unstructured":null,"article-title":"Safety and efficacy of clindamycin phosphate 1.2%-benzoyl peroxide 3% fixed-dose combination gel for the treatment of acne vulgaris: a phase 3, multicenter, randomized, double-blind, active- and vehicle-controlled study","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib67","year":"1980","issue":null,"author":"Smith","volume":"25","first-page":"90","unstructured":null,"article-title":"Benzoyl peroxide lotion (20 percent) in acne","journal-title":"Cutis","doi-asserted-by":null},{"DOI":"10.1016/S0190-9622(83)70211-2","key":"10.1016/j.jaad.2023.12.017_bib68","year":"1983","issue":null,"author":"Chalker","volume":"9","first-page":"933","unstructured":null,"article-title":"A double-blind study of the effectiveness of a 3% erythromycin and 5% benzoyl peroxide combination in the treatment of acne vulgaris","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0190-9622(97)70177-4","key":"10.1016/j.jaad.2023.12.017_bib69","year":"1997","issue":null,"author":"Lookingbill","volume":"37","first-page":"590","unstructured":null,"article-title":"Treatment of acne with a combination clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined results of two double-blind investigations","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1111/j.1365-2230.1992.tb00196.x","key":"10.1016/j.jaad.2023.12.017_bib70","year":"1992","issue":null,"author":"Hughes","volume":"17","first-page":"165","unstructured":null,"article-title":"A double-blind evaluation of topical isotretinoin 0.05%, benzoyl peroxide gel 5% and placebo in patients with acne","journal-title":"Clin Exp Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib71","year":"2012","issue":null,"author":"Jarratt","volume":"11","first-page":"318","unstructured":null,"article-title":"Efficacy and safety of clindamycin-tretinoin gel versus clindamycin or tretinoin alone in acne vulgaris: a randomized, double-blind, vehicle-controlled study","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":"10.1111/j.1365-2133.2011.10332.x","key":"10.1016/j.jaad.2023.12.017_bib72","year":"2011","issue":null,"author":"Trifu","volume":"165","first-page":"177","unstructured":null,"article-title":"Cortexolone 17alpha-propionate 1% cream, a new potent antiandrogen for topical treatment of acne vulgaris. A pilot randomized, double-blind comparative study vs. placebo and tretinoin 0.05% cream","journal-title":"Br J Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib73","year":"2021","issue":null,"author":"Baldwin","volume":"14","first-page":"E53","unstructured":null,"article-title":"Tazarotene 0.045% lotion for moderate-to-severe acne in male and female participants: a phase II post-hoc analysis","journal-title":"J Clin Aesthet Dermatol","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib74","year":"2019","issue":"11","author":"Lain","volume":"18","first-page":"1128","unstructured":null,"article-title":"Tretinoin 0.05% lotion for the once-daily treatment of moderate-to-severe acne vulgaris: impact of gender and Race on efficacy and safety","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib75","year":"2021","issue":"6","author":"Green","volume":"20","first-page":"608","unstructured":null,"article-title":"Tazarotene 0.045% lotion for moderate-to-severe acne patients: pooled phase 3 analysis by age and sex","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib76","year":"2019","issue":"12","author":"Stein Gold","volume":"18","first-page":"1218","unstructured":null,"article-title":"Tretinoin 0.05% lotion for the once-daily treatment of moderate and severe acne vulgaris in females: effect of age on efficacy and tolerability","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib77","year":"2020","issue":"2","author":"Paracha","volume":"34","first-page":"134","unstructured":null,"article-title":"Efficacy and safety of short term use of 0.1% tazarotene gel in the treatment of mild to moderate acne vulgaris: a randomized-vehicle controlled trial","journal-title":"J Postgrad Med Inst","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib78","year":"2007","issue":null,"author":"Alirezai","volume":"17","first-page":"45","unstructured":null,"article-title":"Daily treatment with adapalene gel 0.1% maintains initial improvement of acne vulgaris previously treated with oral lymecycline","journal-title":"Eur J Dermatol","doi-asserted-by":null},{"DOI":"10.1159/000018255","key":"10.1016/j.jaad.2023.12.017_bib79","year":"1999","issue":null,"author":"Glass","volume":"199","first-page":"242","unstructured":null,"article-title":"A placebo-controlled clinical trial to compare a gel containing a combination of isotretinoin (0.05%) and erythromycin (2%) with gels containing isotretinoin (0.05%) or erythromycin (2%) alone in the topical treatment of acne vulgaris","journal-title":"Dermatology (Basel, Switzerland)","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib80","year":"2019","issue":"6","author":"Tanghetti","volume":"18","first-page":"542","unstructured":null,"article-title":"A phase 2, multicenter, double-blind, randomized, vehicle-controlled clinical study to compare the safety and efficacy of a novel tazarotene 0.045% lotion and tazarotene 0.1% cream in the treatment of moderate-to-severe acne vulgaris","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":"10.1016/S0190-9622(87)70200-X","key":"10.1016/j.jaad.2023.12.017_bib81","year":"1987","issue":null,"author":"Chalker","volume":"17","first-page":"251","unstructured":null,"article-title":"Efficacy of topical isotretinoin 0.05% gel in acne vulgaris: results of a multicenter, double-blind investigation","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib82","year":"2019","issue":"11","author":"Harper","volume":"18","first-page":"1147","unstructured":null,"article-title":"Efficacy and tolerability of a novel tretinoin 0.05% lotion for the once-daily treatment of moderate or severe acne vulgaris in adult females","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib83","year":"2007","issue":null,"author":"Lucky","volume":"6","first-page":"981","unstructured":null,"article-title":"Dapsone gel 5% for the treatment of acne vulgaris: safety and efficacy of long-term (1 year) treatment","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib84","year":"2016","issue":"8","author":"Eichenfield","volume":"15","first-page":"962","unstructured":null,"article-title":"Efficacy and safety of once-daily dapsone gel, 7.5% for treatment of adolescents and adults with acne vulgaris: second of two identically designed, large, multicenter, randomized, vehicle-controlled trials","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib85","year":"2016","issue":"5","author":"Stein Gold","volume":"15","first-page":"553","unstructured":null,"article-title":"Efficacy and safety of once-daily dapsone gel, 7.5% for treatment of adolescents and adults with acne vulgaris: first of two identically designed, large, multicenter, randomized, vehicle-controlled trials","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib86","year":"2018","issue":"11","author":"Alexis","volume":"11","first-page":"25","unstructured":null,"article-title":"BPX-01 minocycline topical gel shows promise for the treatment of moderate-tosevere inflammatory acne vulgaris","journal-title":"J Clin Aesthet Dermatol","doi-asserted-by":null},{"DOI":"10.1016/j.jaad.2019.05.078","key":"10.1016/j.jaad.2023.12.017_bib87","year":"2020","issue":"4","author":"Raoof","volume":"82","first-page":"832","unstructured":null,"article-title":"Efficacy and safety of a novel topical minocycline foam for the treatment of moderate to severe acne vulgaris: a phase 3 study","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib88","year":"1988","issue":null,"author":"Pochi","volume":"41","first-page":"132","unstructured":null,"article-title":"Erythromycin 2 percent gel in the treatment of acne vulgaris","journal-title":"Cutis","doi-asserted-by":null},{"DOI":"10.1016/S0190-9622(80)80113-7","key":"10.1016/j.jaad.2023.12.017_bib89","year":"1980","issue":null,"author":"Dobson","volume":"3","first-page":"478","unstructured":null,"article-title":"Topical erythromycin solution in acne: results of a multiclinic trial","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0190-9622(80)80044-2","key":"10.1016/j.jaad.2023.12.017_bib90","year":"1980","issue":null,"author":"Bernstein","volume":"2","first-page":"318","unstructured":null,"article-title":"Topically applied erythromycin in inflammatory acne vulgaris","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0190-9622(85)70074-6","key":"10.1016/j.jaad.2023.12.017_bib91","year":"1985","issue":null,"author":"Lesher","volume":"12","first-page":"526","unstructured":null,"article-title":"An evaluation of a 2% erythromycin ointment in the topical therapy of acne vulgaris","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1001/archderm.1981.01650080036024","key":"10.1016/j.jaad.2023.12.017_bib92","year":"1981","issue":null,"author":"Becker","volume":"117","first-page":"482","unstructured":null,"article-title":"Topical clindamycin therapy for acne vulgaris. A cooperative clinical study","journal-title":"Arch Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1001/jamadermatol.2020.0465","key":"10.1016/j.jaad.2023.12.017_bib93","year":"2020","issue":"6","author":"Hebert","volume":"156","first-page":"621","unstructured":null,"article-title":"Efficacy and safety of topical clascoterone cream, 1%, for treatment in patients with facial acne: two phase 3 randomized clinical trials","journal-title":"JAMA Dermatology","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib94","year":"2019","issue":null,"author":"Mazzetti","volume":"1","first-page":"570","unstructured":null,"article-title":"A phase 2b, randomized, double-blind vehicle controlled, dose escalation study evaluating clascoterone 0.1%, 0.5%, and 1% topical cream in subjects with facial","journal-title":"Acne","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib95","year":"1981","issue":null,"author":"Shalita","volume":"28","first-page":"556","unstructured":null,"article-title":"Treatment of mild and moderate acne vulgaris with salicylic acid in an alcohol-detergent vehicle","journal-title":"Cutis","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib96","year":"1989","issue":null,"author":"Cunliffe","volume":"143","first-page":"31","unstructured":null,"article-title":"Clinical and laboratory studies on treatment with 20% azelaic acid cream for acne","journal-title":"Acta Derm Venereol Suppl","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib97","year":"1989","issue":null,"author":"Katsambas","volume":"143","first-page":"35","unstructured":null,"article-title":"Clinical studies of 20% azelaic acid cream in the treatment of acne vulgaris. Comparison with vehicle and topical tretinoin","journal-title":"Acta Derm Venereol Suppl","doi-asserted-by":null},{"DOI":"10.4103/0378-6323.31892","key":"10.1016/j.jaad.2023.12.017_bib98","year":"2007","issue":null,"author":"Iraji","volume":"73","first-page":"94","unstructured":null,"article-title":"Efficacy of topical azelaic acid gel in the treatment of mild-moderate acne vulgaris","journal-title":"Indian J Dermatol Venereol Leprol","doi-asserted-by":"crossref"},{"DOI":"10.1007/s40257-021-00650-3","key":"10.1016/j.jaad.2023.12.017_bib99","year":"2022","issue":"1","author":"Stein Gold","volume":"23","first-page":"93","unstructured":null,"article-title":"Efficacy and safety of a fixed-dose clindamycin phosphate 1.2%, benzoyl peroxide 3.1%, and adapalene 0.15% gel for moderate-to-severe acne: a randomized phase II study of the first triple-combination drug","journal-title":"Am J Clin Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib100","year":"2015","issue":"4","author":"Harper","volume":"14","first-page":"381","unstructured":null,"article-title":"The efficacy and tolerability of a fixed combination clindamycin (1.2%) and benzoyl peroxide (3.75%) aqueous gel in patients with facial acne vulgaris: gender as a clinically relevant outcome variable","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib101","year":"2014","issue":"9","author":"Pariser","volume":"13","first-page":"1083","unstructured":null,"article-title":"An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% for the once-daily treatment of moderate to severe acne vulgaris","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib102","year":"2015","issue":"5","author":"Cook-Bolden","volume":"8","first-page":"28","unstructured":null,"article-title":"Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and benzoyl peroxide (3.75%) aqueous gel in moderate or severe adolescent acne vulgaris","journal-title":"J Clin Aesthet Dermatol","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib103","year":"2015","issue":"12","author":"Gold","volume":"8","first-page":"22","unstructured":null,"article-title":"Sub-group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate-to-severe acne vulgaris","journal-title":"J Clin Aesthet Dermatol","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib104","year":"2015","issue":"9","author":"Stein Gold","volume":"14","first-page":"969","unstructured":null,"article-title":"Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and benzoyl peroxide (3.75%) aqueous gel in moderate and severe acne vulgaris subpopulations","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib105","year":"2012","issue":null,"author":"Guerra-Tapia","volume":"11","first-page":"714","unstructured":null,"article-title":"Effects of benzoyl peroxide 5% clindamycin combination gel versus adapalene 0.1% on quality of life in patients with mild to moderate acne vulgaris: a randomized single-blind study","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":"10.1111/j.1365-2133.2007.08308.x","key":"10.1016/j.jaad.2023.12.017_bib106","year":"2008","issue":null,"author":"Langner","volume":"158","first-page":"122","unstructured":null,"article-title":"A randomized, single-blind comparison of topical clindamycin + benzoyl peroxide and adapalene in the treatment of mild to moderate facial acne vulgaris","journal-title":"Br J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1080/09546634.2020.1720579","key":"10.1016/j.jaad.2023.12.017_bib107","year":"2021","issue":"8","author":"Dogra","volume":"32","first-page":"925","unstructured":null,"article-title":"Efficacy and safety comparison of combination of 0.04% tretinoin microspheres plus 1% clindamycin versus their monotherapy in patients with acne vulgaris: a phase 3, randomized, double-blind study","journal-title":"J Dermatolog Treat","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib108","year":"2011","issue":null,"author":"Tanghetti","volume":"10","first-page":"783","unstructured":null,"article-title":"Clinical evidence for the role of a topical anti-inflammatory agent in comedonal acne: findings from a randomized study of dapsone gel 5% in combination with tazarotene cream 0.1% in patients with acne vulgaris","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":"10.1007/s40257-018-0352-y","key":"10.1016/j.jaad.2023.12.017_bib109","year":"2018","issue":"2","author":"Dreno","volume":"19","first-page":"275","unstructured":null,"article-title":"Prevention and reduction of atrophic acne scars with adapalene 0.3%/benzoyl peroxide 2.5% gel in subjects with moderate or severe facial acne: results of a 6-month randomized, vehicle-controlled trial using intra-individual comparison","journal-title":"Am J Clin Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib110","year":"2015","issue":"12","author":"Weiss","volume":"14","first-page":"1427","unstructured":null,"article-title":"Customized single-agent therapy management of severe inflammatory acne: a randomized, double-blind, parallel-group, controlled study of a new treatment - adapalene 0.3%-benzoyl peroxide 2.5% gel","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":"10.1007/s40257-016-0178-4","key":"10.1016/j.jaad.2023.12.017_bib111","year":"2016","issue":"3","author":"Stein Gold","volume":"17","first-page":"293","unstructured":null,"article-title":"Moderate and severe inflammatory acne vulgaris effectively treated with single-agent therapy by a new fixed-dose combination adapalene 0.3 %/benzoyl peroxide 2.5 % gel: a randomized, double-blind, parallel-group, controlled study","journal-title":"Am J Clin Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib112","year":"2017","issue":"6","author":"Stein Gold","volume":"16","first-page":"582","unstructured":null,"article-title":"Adapalene/benzoyl peroxide gel 0.3%/2.5%: effective acne therapy regardless of age or gender","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":"10.1111/1346-8138.12979","key":"10.1016/j.jaad.2023.12.017_bib113","year":"2015","issue":"11","author":"Kwon","volume":"42","first-page":"1058","unstructured":null,"article-title":"Do tutorials on application method enhance adapalene-benzoyl peroxide combination gel tolerability in the treatment of acne?","journal-title":"J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1038/ajg.2010.303","key":"10.1016/j.jaad.2023.12.017_bib114","year":"2010","issue":null,"author":"Margolis","volume":"105","first-page":"2610","unstructured":null,"article-title":"Potential association between the oral tetracycline class of antimicrobials used to treat acne and inflammatory bowel disease","journal-title":"Am J Gastroenterol","doi-asserted-by":"crossref"},{"DOI":"10.1001/archderm.139.4.459","key":"10.1016/j.jaad.2023.12.017_bib115","year":"2003","issue":null,"author":"Skidmore","volume":"139","first-page":"459","unstructured":null,"article-title":"Effects of subantimicrobial-dose doxycycline in the treatment of moderate acne","journal-title":"Arch Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib116","year":"2013","issue":null,"author":"Leyden","volume":"12","first-page":"658","unstructured":null,"article-title":"A randomized, phase 2, dose-ranging study in the treatment of moderate to severe inflammatory facial acne vulgaris with doxycycline calcium","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib117","year":"2015","issue":null,"author":"Moore","volume":"14","first-page":"581","unstructured":null,"article-title":"Efficacy and safety of subantimicrobial dose, modified-release doxycycline 40 mg versus doxycycline 100 mg versus placebo for the treatment of inflammatory lesions in moderate and severe acne: a randomized, double-blinded, controlled study","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":"10.1001/archderm.1970.04000040057011","key":"10.1016/j.jaad.2023.12.017_bib118","year":"1970","issue":null,"author":"Plewig","volume":"101","first-page":"435","unstructured":null,"article-title":"Double-blind study of doxycycline in acne vulgaris","journal-title":"Arch Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib119","year":"2006","issue":null,"author":"Fleischer","volume":"78","first-page":"21","unstructured":null,"article-title":"Safety and efficacy of a new extended-release formulation of minocycline","journal-title":"Cutis","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib120","year":"2006","issue":null,"author":"Stewart","volume":"78","first-page":"11","unstructured":null,"article-title":"Dose-ranging efficacy of new once-daily extended-release minocycline for acne vulgaris","journal-title":"Cutis","doi-asserted-by":null},{"DOI":"10.1016/j.jaad.2003.07.021","key":"10.1016/j.jaad.2023.12.017_bib121","year":"2004","issue":null,"author":"Leyden","volume":"50","first-page":"443","unstructured":null,"article-title":"A systemic type 15-reductase inhibitor is ineffective in the treatment of acne vulgaris","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib122","year":"1976","issue":null,"author":"Hersle","volume":"19","first-page":"339","unstructured":null,"article-title":"Minocycline in acne vulgaris: a double-blind study","journal-title":"Curr Ther Res Clin Exp","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib123","year":"2018","issue":null,"author":"Moore","volume":"17","first-page":"987","unstructured":null,"article-title":"Once-daily oral sarecycline 1.5 mg/kg/day is effective for moderate to severe acne vulgaris: results from two identically designed, phase 3, randomized, double-blind clinical trials","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib124","year":"2018","issue":null,"author":"Leyden","volume":"17","first-page":"333","unstructured":null,"article-title":"Efficacy and safety of sarecycline, a novel, once-daily, narrow spectrum antibiotic for the treatment of moderate to severe facial acne vulgaris: results of a phase 2, dose-ranging study","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib125","year":"2019","issue":null,"author":"Pariser","volume":"12","first-page":"E53","unstructured":null,"article-title":"Safety and tolerability of sarecycline for the treatment of acne vulgaris: results from a phase III, multicenter, open-Label study and a phase I phototoxicity study","journal-title":"J Clin Aesthet Dermatol","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib126","year":"2011","issue":null,"author":"Maleszka","volume":"9","first-page":"86","unstructured":null,"article-title":"Pulsed azithromycin treatment is as effective and safe as 2-week-longer daily doxycycline treatment of acne vulgaris: a randomized, double-blind, noninferiority study","journal-title":"Skinmed","doi-asserted-by":null},{"DOI":"10.3109/09546631003762639","key":"10.1016/j.jaad.2023.12.017_bib127","year":"2011","issue":null,"author":"Babaeinejad","volume":"22","first-page":"206","unstructured":null,"article-title":"Comparison of therapeutic effects of oral doxycycline and azithromycin in patients with moderate acne vulgaris: what is the role of age?","journal-title":"J Dermatol Treat","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib128","year":"2014","issue":null,"author":"Ullah","volume":"26","first-page":"64","unstructured":null,"article-title":"Comparison of oral azithromycin with oral doxycycline in the treatment of acne vulgaris","journal-title":"J Ayub Med Coll Abbottabad","doi-asserted-by":null},{"DOI":"10.1111/j.1365-2230.2005.01769.x","key":"10.1016/j.jaad.2023.12.017_bib129","year":"2005","issue":null,"author":"Kus","volume":"30","first-page":"215","unstructured":null,"article-title":"Comparison of efficacy of azithromycin vs. doxycycline in the treatment of acne vulgaris","journal-title":"Clin Exp Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1097/AOG.0b013e318187e1c5","key":"10.1016/j.jaad.2023.12.017_bib130","year":"2008","issue":null,"author":"Maloney","volume":"112","first-page":"773","unstructured":null,"article-title":"Treatment of acne using a 3-milligram drospirenone/20-microgram ethinyl estradiol oral contraceptive administered in a 24/4 regimen: a randomized controlled trial","journal-title":"Obstet Gynecol","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0015-0282(01)01938-0","key":"10.1016/j.jaad.2023.12.017_bib131","year":"2001","issue":null,"author":"Thiboutot","volume":"76","first-page":"461","unstructured":null,"article-title":"A randomized, controlled trial of a low-dose contraceptive containing 20 microg of ethinyl estradiol and 100 microg of levonorgestrel for acne treatment","journal-title":"Fertil Steril","doi-asserted-by":"crossref"},{"DOI":"10.1067/mjd.2002.122192","key":"10.1016/j.jaad.2023.12.017_bib132","year":"2002","issue":null,"author":"Leyden","volume":"47","first-page":"399","unstructured":null,"article-title":"Efficacy of a low-dose oral contraceptive containing 20 microg of ethinyl estradiol and 100 microg of levonorgestrel for the treatment of moderate acne: a randomized, placebo-controlled trial","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0029-7844(97)00059-8","key":"10.1016/j.jaad.2023.12.017_bib133","year":"1997","issue":null,"author":"Redmond","volume":"89","first-page":"615","unstructured":null,"article-title":"Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: a randomized, placebo-controlled trial","journal-title":"Obstet Gynecol","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0190-9622(97)70112-9","key":"10.1016/j.jaad.2023.12.017_bib134","year":"1997","issue":null,"author":"Lucky","volume":"37","first-page":"746","unstructured":null,"article-title":"Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.contraception.2008.10.010","key":"10.1016/j.jaad.2023.12.017_bib135","year":"2009","issue":null,"author":"Palombo-Kinne","volume":"79","first-page":"282","unstructured":null,"article-title":"Efficacy of a combined oral contraceptive containing 0.030 mg ethinylestradiol/2 mg dienogest for the treatment of papulopustular acne in comparison with placebo and 0.035 mg ethinylestradiol/2 mg cyproterone acetate","journal-title":"Contraception","doi-asserted-by":"crossref"},{"DOI":"10.1053/cjwh.2001.25638","key":"10.1016/j.jaad.2023.12.017_bib136","year":"2001","issue":null,"author":"Maloney JM Arbit","volume":"1","first-page":"123","unstructured":null,"article-title":"Use of low-dose oral contraceptive containing norethindrone acetate and ethinyl estradiol in the treatment of moderate acne vulgaris","journal-title":"Clin J Wom Health","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.contraception.2007.11.003","key":"10.1016/j.jaad.2023.12.017_bib137","year":"2008","issue":null,"author":"Koltun","volume":"77","first-page":"249","unstructured":null,"article-title":"Efficacy and safety of 3 mg drospirenone/20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled trial","journal-title":"Contraception","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.contraception.2009.02.016","key":"10.1016/j.jaad.2023.12.017_bib138","year":"2009","issue":null,"author":"Plewig","volume":"80","first-page":"25","unstructured":null,"article-title":"Efficacy of an oral contraceptive containing EE 0.03 mg and CMA 2 mg (Belara) in moderate acne resolution: a randomized, double-blind, placebo-controlled phase III trial","journal-title":"Contraception","doi-asserted-by":"crossref"},{"DOI":"10.1080/13625180008500411","key":"10.1016/j.jaad.2023.12.017_bib139","year":"2000","issue":null,"author":"Katz","volume":"5","first-page":"248","unstructured":null,"article-title":"Effect of a desogestrel-containing oral contraceptive on the skin","journal-title":"Eur J Contracept Reprod Health Care","doi-asserted-by":"crossref"},{"DOI":"10.1111/1346-8138.15559","key":"10.1016/j.jaad.2023.12.017_bib140","year":"2020","issue":null,"author":"Patiyasikunt","volume":"47","first-page":"1411","unstructured":null,"article-title":"Efficacy and tolerability of low-dose spironolactone and topical benzoyl peroxide in adult female acne: a randomized, double-blind, placebo-controlled trial","journal-title":"J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1111/j.1365-2133.1984.tb04045.x","key":"10.1016/j.jaad.2023.12.017_bib141","year":"1984","issue":null,"author":"Goodfellow","volume":"111","first-page":"209","unstructured":null,"article-title":"Oral spironolactone improves acne vulgaris and reduces sebum excretion","journal-title":"Br J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1111/j.1365-2133.1986.tb05722.x","key":"10.1016/j.jaad.2023.12.017_bib142","year":"1986","issue":null,"author":"Muhlemann","volume":"115","first-page":"227","unstructured":null,"article-title":"Oral spironolactone: an effective treatment for acne vulgaris in women","journal-title":"Br J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1001/jamadermatol.2020.5468","key":"10.1016/j.jaad.2023.12.017_bib143","year":"2021","issue":null,"author":"Barbieri","volume":"157","first-page":"296","unstructured":null,"article-title":"Temporal trends and clinician variability in potassium monitoring of healthy young women treated for acne with spironolactone","journal-title":"JAMA Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1159/000471799","key":"10.1016/j.jaad.2023.12.017_bib144","year":"2017","issue":null,"author":"Grandhi","volume":"233","first-page":"141","unstructured":null,"article-title":"Spironolactone for the treatment of acne: a 4-year retrospective study","journal-title":"Dermatology","doi-asserted-by":"crossref"},{"DOI":"10.1001/jamadermatol.2015.34","key":"10.1016/j.jaad.2023.12.017_bib145","year":"2015","issue":null,"author":"Plovanich","volume":"151","first-page":"941","unstructured":null,"article-title":"Low usefulness of potassium monitoring among healthy young women taking spironolactone for acne","journal-title":"JAMA Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1007/s00266-006-0081-0","key":"10.1016/j.jaad.2023.12.017_bib146","year":"2006","issue":null,"author":"Sato","volume":"30","first-page":"689","unstructured":null,"article-title":"Anti-androgenic therapy using oral spironolactone for acne vulgaris in Asians","journal-title":"Aesthetic Plast Surg","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.ijwd.2019.04.024","key":"10.1016/j.jaad.2023.12.017_bib147","year":"2019","issue":null,"author":"Thiede","volume":"5","first-page":"155","unstructured":null,"article-title":"Hyperkalemia in women with acne exposed to oral spironolactone: a retrospective study from the RADAR (Research on Adverse Drug Events and Reports) program","journal-title":"Int J Womens Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.4103/0378-6323.86482","key":"10.1016/j.jaad.2023.12.017_bib148","year":"2011","issue":null,"author":"Agarwal","volume":"77","first-page":"688","unstructured":null,"article-title":"Oral isotretinoin in different dose regimens for acne vulgaris: a randomized comparative trial","journal-title":"Indian J Dermatol Venereol Leprol","doi-asserted-by":"crossref"},{"DOI":"10.1007/s00403-007-0777-2","key":"10.1016/j.jaad.2023.12.017_bib149","year":"2007","issue":null,"author":"Akman","volume":"299","first-page":"467","unstructured":null,"article-title":"Treatment of acne with intermittent and conventional isotretinoin: a randomized, controlled multicenter study","journal-title":"Arch Dermatol Res","doi-asserted-by":"crossref"},{"DOI":"10.1111/j.1365-2133.2010.10152.x","key":"10.1016/j.jaad.2023.12.017_bib150","year":"2011","issue":null,"author":"Lee","volume":"164","first-page":"1369","unstructured":null,"article-title":"Effectiveness of conventional, low-dose and intermittent oral isotretinoin in the treatment of acne: a randomized, controlled comparative study","journal-title":"Br J Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib151","year":"2014","issue":null,"author":"Webster","volume":"13","first-page":"665","unstructured":null,"article-title":"Results of a phase III, double-blind, randomized, parallel-group, non-inferiority study evaluating the safety and efficacy of isotretinoin-Lidose in patients with severe recalcitrant nodular acne","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib152","year":"2016","issue":"1","author":"Tangjaturonrusamee","volume":"98","first-page":"56","unstructured":null,"article-title":"Comparison of pneumatic broadband light plus adapalene gel 0.3% versus adapalene gel 0.3% monotherapy in the treatment of mild to moderate acne","journal-title":"Cutis","doi-asserted-by":null},{"DOI":"10.1016/S0190-9622(96)90443-0","key":"10.1016/j.jaad.2023.12.017_bib153","year":"1996","issue":null,"author":"Shalita","volume":"34","first-page":"482","unstructured":null,"article-title":"A comparison of the efficacy and safety of adapalene gel 0.1% and tretinoin gel 0.025% in the treatment of acne vulgaris: a multicenter trial","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0190-9622(98)70141-0","key":"10.1016/j.jaad.2023.12.017_bib154","year":"1998","issue":null,"author":"Lucky","volume":"38","first-page":"S17","unstructured":null,"article-title":"Comparative efficacy and safety of two 0.025% tretinoin gels: results from a multicenter, double-blind, parallel study","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1080/09546634.2019.1587884","key":"10.1016/j.jaad.2023.12.017_bib155","year":"2020","issue":"2","author":"Harper","volume":"31","first-page":"160","unstructured":null,"article-title":"Novel tretinoin 0.05% lotion for the once-daily treatment of moderate-to-severe acne vulgaris: assessment of safety and tolerability in subgroups","journal-title":"J Dermatol Treat","doi-asserted-by":"crossref"},{"DOI":"10.1046/j.1365-2133.1998.1390s2017.x","key":"10.1016/j.jaad.2023.12.017_bib156","year":"1998","issue":"Suppl 52","author":"Dunlap","volume":"139","first-page":"17","unstructured":null,"article-title":"Adapalene 0.1% gel for the treatment of acne vulgaris: its superiority compared to tretinoin 0.025% cream in skin tolerance and patient preference","journal-title":"Br J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1067/mjd.2000.108322","key":"10.1016/j.jaad.2023.12.017_bib157","year":"2000","issue":null,"author":"Kakita","volume":"43","first-page":"S51","unstructured":null,"article-title":"Tazarotene versus tretinoin or adapalene in the treatment of acne vulgaris","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib158","year":"2001","issue":null,"author":"Webster","volume":"67","first-page":"4","unstructured":null,"article-title":"Efficacy and tolerability of once-daily tazarotene 0.1% gel versus once-daily tretinoin 0.025% gel in the treatment of facial acne vulgaris: a randomized trial","journal-title":"Cutis","doi-asserted-by":null},{"DOI":"10.1046/j.1365-2133.1998.1390s2034.x","key":"10.1016/j.jaad.2023.12.017_bib159","year":"1998","issue":"Suppl 52","author":"Galvin","volume":"139","first-page":"34","unstructured":null,"article-title":"Comparative tolerance of adapalene 0.1% gel and six different tretinoin formulations","journal-title":"Br J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1111/j.1365-2133.1971.tb02533.x","key":"10.1016/j.jaad.2023.12.017_bib160","year":"1971","issue":null,"author":"Pedace","volume":"84","first-page":"465","unstructured":null,"article-title":"Topical retinoic acid in acne vulgaris","journal-title":"Br J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1159/000251602","key":"10.1016/j.jaad.2023.12.017_bib161","year":"1974","issue":null,"author":"Christiansen","volume":"148","first-page":"82","unstructured":null,"article-title":"Topical tretinoin, vitamin A acid (Airol) in acne vulgaris. A controlled clinical trial","journal-title":"Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0190-9622(97)70056-2","key":"10.1016/j.jaad.2023.12.017_bib162","year":"1997","issue":null,"author":"Cunliffe","volume":"36","first-page":"S126","unstructured":null,"article-title":"Clinical efficacy and safety comparison of adapalene gel and tretinoin gel in the treatment of acne vulgaris: Europe and U.S. multicenter trials","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib163","year":"1976","issue":null,"author":"Krishnan","volume":"216","first-page":"106","unstructured":null,"article-title":"Comparison of two concentrations of tretinoin solution in the topical treatment of acne vulgaris","journal-title":"Practitioner","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib164","year":"1978","issue":null,"author":"Cunliffe","volume":"220","first-page":"479","unstructured":null,"article-title":"Benzoyl peroxide in acne","journal-title":"Practitioner","doi-asserted-by":null},{"DOI":"10.1111/j.1600-0560.1974.tb00628.x","key":"10.1016/j.jaad.2023.12.017_bib165","year":"1974","issue":null,"author":"Fulton","volume":"1","first-page":"191","unstructured":null,"article-title":"Studies on the mechanism of action to topical benzoyl peroxide and vitamin A acid in acne vulgaris","journal-title":"J Cutan Pathol","doi-asserted-by":"crossref"},{"DOI":"10.1159/000249352","key":"10.1016/j.jaad.2023.12.017_bib166","year":"1986","issue":null,"author":"Fyrand","volume":"172","first-page":"263","unstructured":null,"article-title":"Water-based versus alcohol-based benzoyl peroxide preparations in the treatment of acne vulgaris","journal-title":"Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1111/j.1365-4362.1986.tb04534.x","key":"10.1016/j.jaad.2023.12.017_bib167","year":"1986","issue":null,"author":"Mills","volume":"25","first-page":"664","unstructured":null,"article-title":"Comparing 2.5%, 5%, and 10% benzoyl peroxide on inflammatory acne vulgaris","journal-title":"Int J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1080/000155502320323216","key":"10.1016/j.jaad.2023.12.017_bib168","year":"2002","issue":null,"author":"Mills","volume":"82","first-page":"260","unstructured":null,"article-title":"Bacterial resistance and therapeutic outcome following three months of topical acne therapy with 2% erythromycin gel versus its vehicle","journal-title":"Acta Derm Venereol","doi-asserted-by":"crossref"},{"DOI":"10.1001/archdermatol.2009.186","key":"10.1016/j.jaad.2023.12.017_bib169","year":"2009","issue":null,"author":"Dubina","volume":"145","first-page":"1027","unstructured":null,"article-title":"Interaction of topical sulfacetamide and topical dapsone with benzoyl peroxide","journal-title":"Arch Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1001/archderm.1986.01660170113031","key":"10.1016/j.jaad.2023.12.017_bib170","year":"1986","issue":null,"author":"Parry","volume":"122","first-page":"583","unstructured":null,"article-title":"Pseudomembranous colitis caused by topical clindamycin phosphate","journal-title":"Arch Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib171","year":"2010","issue":null,"author":"Yentzer","volume":"86","first-page":"103","unstructured":null,"article-title":"Simplifying regimens promotes greater adherence and outcomes with topical acne medications: a randomized controlled trial","journal-title":"Cutis","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib172","year":"2019","issue":null,"author":"Rosette","volume":"18","first-page":"412","unstructured":null,"article-title":"Cortexolone 17alpha-propionate (clascoterone) is a novel androgen receptor antagonist that inhibits production of lipids and inflammatory cytokines from sebocytes in vitro","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib173","year":"2011","issue":null,"author":"Kircik","volume":"10","first-page":"586","unstructured":null,"article-title":"Efficacy and safety of azelaic acid (AzA) gel 15% in the treatment of post-inflammatory hyperpigmentation and acne: a 16-week, baseline-controlled study","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":"10.1016/j.jaad.2013.09.010","key":"10.1016/j.jaad.2023.12.017_bib174","year":"2014","issue":null,"author":"Murase","volume":"70","first-page":"401.e1","unstructured":null,"article-title":"Safety of dermatologic medications in pregnancy and lactation: part I. Pregnancy","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1007/s13555-022-00854-3","key":"10.1016/j.jaad.2023.12.017_bib175","year":"2023","issue":null,"author":"Ly","volume":"13","first-page":"115","unstructured":null,"article-title":"Treatment of acne vulgaris during pregnancy and lactation: a Narrative review","journal-title":"Dermatol Ther","doi-asserted-by":"crossref"},{"DOI":"10.1111/ajd.12075","key":"10.1016/j.jaad.2023.12.017_bib176","year":"2014","issue":null,"author":"Perret","volume":"55","first-page":"111","unstructured":null,"article-title":"Non-antibiotic properties of tetracyclines and their clinical application in dermatology","journal-title":"Australas J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1001/jamadermatol.2018.4944","key":"10.1016/j.jaad.2023.12.017_bib177","year":"2019","issue":null,"author":"Barbieri","volume":"155","first-page":"290","unstructured":null,"article-title":"Trends in oral antibiotic prescription in dermatology, 2008 to 2016","journal-title":"JAMA Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib178","year":"2025","issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1001/archdermatol.2011.355","key":"10.1016/j.jaad.2023.12.017_bib179","year":"2012","issue":null,"author":"Margolis","volume":"148","first-page":"326","unstructured":null,"article-title":"Association of pharyngitis with oral antibiotic use for the treatment of acne: a cross-sectional and prospective cohort study","journal-title":"Arch Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1056/NEJM197803092981003","key":"10.1016/j.jaad.2023.12.017_bib180","year":"1978","issue":null,"author":"Bartlett","volume":"298","first-page":"531","unstructured":null,"article-title":"Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia","journal-title":"N Engl J Med","doi-asserted-by":"crossref"},{"DOI":"10.1146/annurev-micro-090110-102824","key":"10.1016/j.jaad.2023.12.017_bib181","year":"2011","issue":null,"author":"Carroll","volume":"65","first-page":"501","unstructured":null,"article-title":"Biology of Clostridium difficile: implications for epidemiology and diagnosis","journal-title":"Annu Rev Microbiol","doi-asserted-by":"crossref"},{"DOI":"10.15585/mmwr.rr6506a1","key":"10.1016/j.jaad.2023.12.017_bib312","year":"2016","issue":"6","author":"Sanchez","volume":"65","first-page":"1","unstructured":null,"article-title":"Core elements of outpatient antibiotic stewardship","journal-title":"MMWR Recomm Rep","doi-asserted-by":"crossref"},{"DOI":"10.1111/jdv.13776","key":"10.1016/j.jaad.2023.12.017_bib182","year":"2016","issue":null,"author":"Nast","volume":"30","first-page":"1261","unstructured":null,"article-title":"European evidence-based (S3) guideline for the treatment of acne - update 2016 - short version","journal-title":"J Eur Acad Dermatol Venereol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib183","year":"2019","issue":null,"author":"Oon","volume":"12","first-page":"34","unstructured":null,"article-title":"Acne management guidelines by the Dermatological Society of Singapore","journal-title":"J Clin Aesthet Dermatol","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib184","year":"2010","issue":null,"author":"Gold","volume":"85","first-page":"94","unstructured":null,"article-title":"Effective and safe combination therapy for severe acne vulgaris: a randomized, vehicle-controlled, double-blind study of adapalene 0.1%-benzoyl peroxide 2.5% fixed-dose combination gel with doxycycline hyclate 100 mg","journal-title":"Cutis","doi-asserted-by":null},{"DOI":"10.1001/archderm.142.5.605","key":"10.1016/j.jaad.2023.12.017_bib185","year":"2006","issue":null,"author":"Leyden","volume":"142","first-page":"605","unstructured":null,"article-title":"Comparison of tazarotene and minocycline maintenance therapies in acne vulgaris: a multicenter, double-blind, randomized, parallel-group study","journal-title":"Arch Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib186","year":"2012","issue":null,"author":"Tan","volume":"11","first-page":"174","unstructured":null,"article-title":"Short-term combination therapy and long-term relapse prevention in the treatment of severe acne vulgaris","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":"10.1001/archderm.142.5.597","key":"10.1016/j.jaad.2023.12.017_bib187","year":"2006","issue":null,"author":"Thiboutot","volume":"142","first-page":"597","unstructured":null,"article-title":"Adapalene gel, 0.1%, as maintenance therapy for acne vulgaris: a randomized, controlled, investigator-blind follow-up of a recent combination study","journal-title":"Arch Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1111/j.1346-8138.2012.01626.x","key":"10.1016/j.jaad.2023.12.017_bib188","year":"2012","issue":null,"author":"Moon","volume":"39","first-page":"833","unstructured":null,"article-title":"Antibiotic resistance of microbial strains isolated from Korean acne patients","journal-title":"J Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib189","year":"2008","issue":null,"author":"Toossi","volume":"7","first-page":"1149","unstructured":null,"article-title":"Subantimicrobial-dose doxycycline in the treatment of moderate facial acne","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":"10.1016/S0140-6736(04)17591-0","key":"10.1016/j.jaad.2023.12.017_bib190","year":"2004","issue":null,"author":"Ozolins","volume":"364","first-page":"2188","unstructured":null,"article-title":"Comparison of five antimicrobial regimens for treatment of mild to moderate inflammatory facial acne vulgaris in the community: randomised controlled trial","journal-title":"Lancet","doi-asserted-by":"crossref"},{"DOI":"10.1002/14651858.CD004425.pub5","key":"10.1016/j.jaad.2023.12.017_bib191","year":"2012","issue":null,"author":"Arowojolu","volume":"6","first-page":null,"unstructured":null,"article-title":"Combined oral contraceptive pills for treatment of acne","journal-title":"Cochrane Database Syst Rev","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib192","year":"2012","issue":null,"author":"Arrington","volume":"90","first-page":"83","unstructured":null,"article-title":"Combined oral contraceptives for the treatment of acne: a practical guide","journal-title":"Cutis","doi-asserted-by":null},{"DOI":"10.1111/j.1529-8019.2009.01261.x","key":"10.1016/j.jaad.2023.12.017_bib193","year":"2009","issue":null,"author":"Harper","volume":"22","first-page":"452","unstructured":null,"article-title":"Should dermatologists prescribe hormonal contraceptives for acne?","journal-title":"Dermatol Ther","doi-asserted-by":"crossref"},{"DOI":"10.3109/09513590009167685","key":"10.1016/j.jaad.2023.12.017_bib194","year":"2000","issue":null,"author":"Rabe","volume":"14","first-page":"223","unstructured":null,"article-title":"Inhibition of skin 5 alpha-reductase by oral contraceptive progestins in vitro","journal-title":"Gynecol Endocrinol","doi-asserted-by":"crossref"},{"DOI":"10.1097/AOG.0000000000003880","key":"10.1016/j.jaad.2023.12.017_bib195","year":"2020","issue":null,"author":"Barbieri","volume":"135","first-page":"1306","unstructured":null,"article-title":"Influence of contraception class on incidence and severity of acne vulgaris","journal-title":"Obstet Gynecol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib196","year":"2016","issue":null,"author":"Lortscher","volume":"15","first-page":"670","unstructured":null,"article-title":"Hormonal contraceptives and acne: a retrospective analysis of 2147 patients","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib197","year":"2012","issue":null,"author":"Davtyan","volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.2165/11535450-000000000-00000","key":"10.1016/j.jaad.2023.12.017_bib198","year":"2010","issue":null,"author":"Kelly","volume":"30","first-page":"325","unstructured":null,"article-title":"Effects of oral contraceptives containing ethinylestradiol with either drospirenone or levonorgestrel on various parameters associated with well-being in healthy women: a randomized, single-blind, parallel-group, multicentre study","journal-title":"Clin Drug Investig","doi-asserted-by":"crossref"},{"DOI":"10.2340/0001555564517523","key":"10.1016/j.jaad.2023.12.017_bib199","year":"1984","issue":null,"author":"Palatsi","volume":"64","first-page":"517","unstructured":null,"article-title":"Serum total and unbound testosterone and sex hormone binding globulin (SHBG) in female acne patients treated with two different oral contraceptives","journal-title":"Acta Derm Venereol","doi-asserted-by":"crossref"},{"DOI":"10.1067/mob.2003.294","key":"10.1016/j.jaad.2023.12.017_bib200","year":"2003","issue":null,"author":"Rosen","volume":"188","first-page":"1158","unstructured":null,"article-title":"A randomized controlled trial of second- versus third-generation oral contraceptives in the treatment of acne vulgaris","journal-title":"Am J Obstet Gynecol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.contraception.2003.12.017","key":"10.1016/j.jaad.2023.12.017_bib201","year":"2004","issue":null,"author":"Winkler","volume":"69","first-page":"469","unstructured":null,"article-title":"Cycle control, quality of life and acne with two low-dose oral contraceptives containing 20 microg ethinylestradiol","journal-title":"Contraception","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.contraception.2014.06.002","key":"10.1016/j.jaad.2023.12.017_bib202","year":"2014","issue":null,"author":"Jaisamrarn","volume":"90","first-page":"535","unstructured":null,"article-title":"A comparison of multiphasic oral contraceptives containing norgestimate or desogestrel in acne treatment: a randomized trial","journal-title":"Contraception","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib203","year":"2004","issue":null,"author":"Thorneycroft","volume":"74","first-page":"123","unstructured":null,"article-title":"Superiority of a combined contraceptive containing drospirenone to a triphasic preparation containing norgestimate in acne treatment","journal-title":"Cutis","doi-asserted-by":null},{"DOI":"10.1016/S0010-7824(99)00093-1","key":"10.1016/j.jaad.2023.12.017_bib204","year":"1999","issue":null,"author":"Thorneycroft","volume":"60","first-page":"255","unstructured":null,"article-title":"Effect of low-dose oral contraceptives on androgenic markers and acne","journal-title":"Contraception","doi-asserted-by":"crossref"},{"DOI":"10.1001/jama.285.17.2232","key":"10.1016/j.jaad.2023.12.017_bib205","year":"2001","issue":null,"author":"Stewart","volume":"285","first-page":"2232","unstructured":null,"article-title":"Clinical breast and pelvic examination requirements for hormonal contraception: current practice vs evidence","journal-title":"JAMA","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib206","year":"2016","issue":null,"author":"Curtis","volume":"65","first-page":"1","unstructured":null,"article-title":"U.S. Selected practice recommendations for contraceptive use, 2016","journal-title":"MMWR Recomm Rep","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib207","year":"2012","issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib208","year":"2016","issue":null,"author":"Curtis","volume":"65","first-page":"1","unstructured":null,"article-title":"U.S. Medical eligibility criteria for contraceptive use, 2016","journal-title":"MMWR Recomm Rep","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib209","year":"2011","issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1016/j.clindermatol.2009.03.006","key":"10.1016/j.jaad.2023.12.017_bib210","year":"2010","issue":null,"author":"Katsambas","volume":"28","first-page":"17","unstructured":null,"article-title":"Hormonal therapy for acne: why not as first line therapy? facts and controversies","journal-title":"Clin Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1158/1055-9965.EPI-13-0298","key":"10.1016/j.jaad.2023.12.017_bib211","year":"2013","issue":null,"author":"Gierisch","volume":"22","first-page":"1931","unstructured":null,"article-title":"Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review","journal-title":"Cancer Epidemiol Biomarkers Prev","doi-asserted-by":"crossref"},{"DOI":"10.1097/AOG.0b013e318291c235","key":"10.1016/j.jaad.2023.12.017_bib212","year":"2013","issue":null,"author":"Havrilesky","volume":"122","first-page":"139","unstructured":null,"article-title":"Oral contraceptive pills as primary prevention for ovarian cancer: a systematic review and meta-analysis","journal-title":"Obstet Gynecol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.ajog.2017.02.002","key":"10.1016/j.jaad.2023.12.017_bib213","year":"2017","issue":null,"author":"Iversen","volume":"216","first-page":"580.e1","unstructured":null,"article-title":"Lifetime cancer risk and combined oral contraceptives: the Royal College of general practitioners' oral contraception study","journal-title":"Am J Obstet Gynecol","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0140-6736(07)61684-5","key":"10.1016/j.jaad.2023.12.017_bib214","year":"2007","issue":null,"author":"Appleby","volume":"370","first-page":"1609","unstructured":null,"article-title":"Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies","journal-title":"Lancet","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib215","year":"2016","issue":null,"author":"Roura","volume":"11","first-page":null,"unstructured":null,"article-title":"The influence of hormonal factors on the risk of developing cervical cancer and pre-cancer: results from the EPIC cohort","journal-title":"PLoS One","doi-asserted-by":null},{"DOI":"10.1097/AOG.0b013e3181cb50b5","key":"10.1016/j.jaad.2023.12.017_bib216","year":"2010","issue":null,"author":null,"volume":"115","first-page":"206","unstructured":null,"article-title":"ACOG practice bulletin no. 110: noncontraceptive uses of hormonal contraceptives","journal-title":"Obstet Gynecol","doi-asserted-by":"crossref"},{"DOI":"10.1097/AOG.0000000000004659","key":"10.1016/j.jaad.2023.12.017_bib217","year":"2022","issue":null,"author":null,"volume":"139","first-page":"350","unstructured":null,"article-title":"Patient-centered contraceptive counseling: ACOG Committee statement number 1","journal-title":"Obstet Gynecol","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0190-9622(97)80322-2","key":"10.1016/j.jaad.2023.12.017_bib218","year":"1997","issue":null,"author":"Helms","volume":"36","first-page":"705","unstructured":null,"article-title":"Oral contraceptive failure rates and oral antibiotics","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1001/archderm.1994.01690030128027","key":"10.1016/j.jaad.2023.12.017_bib219","year":"1994","issue":null,"author":"London","volume":"130","first-page":"392","unstructured":null,"article-title":"Frequency of pregnancy in acne patients taking oral antibiotics and oral contraceptives","journal-title":"Arch Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1097/00006250-200606000-00055","key":"10.1016/j.jaad.2023.12.017_bib220","year":"2006","issue":null,"author":null,"volume":"107","first-page":"1453","unstructured":null,"article-title":"ACOG practice bulletin. No. 73: use of hormonal contraception in women with coexisting medical conditions","journal-title":"Obstet Gynecol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaad.2007.09.024","key":"10.1016/j.jaad.2023.12.017_bib221","year":"2008","issue":null,"author":"Krunic","volume":"58","first-page":"60","unstructured":null,"article-title":"Efficacy and tolerance of acne treatment using both spironolactone and a combined contraceptive containing drospirenone","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1186/1472-6904-11-23","key":"10.1016/j.jaad.2023.12.017_bib222","year":"2011","issue":null,"author":"Bird","volume":"11","first-page":"23","unstructured":null,"article-title":"The association between drospirenone and hyperkalemia: a comparative-safety study","journal-title":"BMC Clin Pharmacol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.contraception.2021.05.002","key":"10.1016/j.jaad.2023.12.017_bib223","year":"2021","issue":null,"author":"Creinin","volume":"104","first-page":"222","unstructured":null,"article-title":"Estetrol-drospirenone combination oral contraceptive: North American phase 3 efficacy and safety results","journal-title":"Contraception","doi-asserted-by":"crossref"},{"DOI":"10.1139/o79-131","key":"10.1016/j.jaad.2023.12.017_bib224","year":"1979","issue":null,"author":"Boisselle","volume":"57","first-page":"1042","unstructured":null,"article-title":"Interaction of spironolactone with rat skin androgen receptor","journal-title":"Can J Biochem","doi-asserted-by":"crossref"},{"DOI":"10.1016/0024-3205(74)90330-0","key":"10.1016/j.jaad.2023.12.017_bib225","year":"1974","issue":null,"author":"Menard","volume":"15","first-page":"1639","unstructured":null,"article-title":"Spironolactone and cytochrome P-450: impairment of steroid hydroxylation in the adrenal cortex","journal-title":"Life Sci","doi-asserted-by":"crossref"},{"DOI":"10.1210/endo-94-6-1628","key":"10.1016/j.jaad.2023.12.017_bib226","year":"1974","issue":null,"author":"Menard","volume":"94","first-page":"1628","unstructured":null,"article-title":"Spironolactone and testicular cytochrome P-450: decreased testosterone formation in several species and changes in hepatic drug metabolism","journal-title":"Endocrinology","doi-asserted-by":"crossref"},{"DOI":"10.1210/jcem-46-2-338","key":"10.1016/j.jaad.2023.12.017_bib227","year":"1978","issue":null,"author":"Rifka","volume":"46","first-page":"338","unstructured":null,"article-title":"Interaction of digitalis and spironolactone with human sex steroid receptors","journal-title":"J Clin Endocrinol Metab","doi-asserted-by":"crossref"},{"DOI":"10.1159/000211271","key":"10.1016/j.jaad.2023.12.017_bib228","year":"1994","issue":null,"author":"Zouboulis","volume":"7","first-page":"33","unstructured":null,"article-title":"Androgens affect the activity of human sebocytes in culture in a manner dependent on the localization of the sebaceous glands and their effect is antagonized by spironolactone","journal-title":"Skin Pharmacol","doi-asserted-by":"crossref"},{"DOI":"10.1016/0022-4731(85)90236-5","key":"10.1016/j.jaad.2023.12.017_bib229","year":"1985","issue":null,"author":"Serafini","volume":"23","first-page":"191","unstructured":null,"article-title":"The effect of spironolactone on genital skin 5 alpha-reductase activity","journal-title":"J Steroid Biochem","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib230","year":"2018","issue":null,"author":"Barbieri","volume":"17","first-page":"632","unstructured":null,"article-title":"Frequency of treatment switching for spironolactone compared to oral tetracycline-class antibiotics for women with acne: a retrospective cohort study 2010-2016","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":"10.1007/s40257-016-0245-x","key":"10.1016/j.jaad.2023.12.017_bib231","year":"2017","issue":null,"author":"Layton","volume":"18","first-page":"169","unstructured":null,"article-title":"Oral spironolactone for acne vulgaris in adult females: a hybrid systematic review","journal-title":"Am J Clin Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaad.2020.12.071","key":"10.1016/j.jaad.2023.12.017_bib232","year":"2021","issue":null,"author":"Garg","volume":"84","first-page":"1348","unstructured":null,"article-title":"Long-term use of spironolactone for acne in women: a case series of 403 patients","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1177/120347540200600604","key":"10.1016/j.jaad.2023.12.017_bib233","year":"2002","issue":null,"author":"Shaw","volume":"6","first-page":"541","unstructured":null,"article-title":"Long-term safety of spironolactone in acne: results of an 8-year followup study","journal-title":"J Cutan Med Surg","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib234","year":"2023","issue":null,"author":"Santer","volume":"381","first-page":null,"unstructured":null,"article-title":"Effectiveness of spironolactone for women with acne vulgaris (SAFA) in England and Wales: pragmatic, multicentre, phase 3, double blind, randomised controlled trial","journal-title":"BMJ","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib235","year":"2013","issue":null,"author":"Zeichner","volume":"12","first-page":"1416","unstructured":null,"article-title":"Evaluating and treating the adult female patient with acne","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":"10.1016/j.jaad.2018.10.023","key":"10.1016/j.jaad.2023.12.017_bib236","year":"2019","issue":null,"author":"Liszewski","volume":"80","first-page":"1147","unstructured":null,"article-title":"Lack of evidence for feminization of males exposed to spironolactone in utero: a systematic review","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1001/jamadermatol.2021.5866","key":"10.1016/j.jaad.2023.12.017_bib237","year":"2022","issue":null,"author":"Bommareddy","volume":"158","first-page":"275","unstructured":null,"article-title":"Association of spironolactone use with risk of cancer: a systematic review and meta-analysis","journal-title":"JAMA Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1001/archderm.1983.01650300034012","key":"10.1016/j.jaad.2023.12.017_bib238","year":"1983","issue":null,"author":"Levine","volume":"119","first-page":"480","unstructured":null,"article-title":"Intralesional corticosteroids in the treatment of nodulocystic acne","journal-title":"Arch Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaad.2019.02.067","key":"10.1016/j.jaad.2023.12.017_bib239","year":"2019","issue":null,"author":"Alikhan","volume":"81","first-page":"76","unstructured":null,"article-title":"North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: part I: diagnosis, evaluation, and the use of complementary and procedural management","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1007/s00266-008-9152-8","key":"10.1016/j.jaad.2023.12.017_bib240","year":"2008","issue":null,"author":"Hochman","volume":"32","first-page":"705","unstructured":null,"article-title":"Intralesional triamcinolone acetonide for keloid treatment: a systematic review","journal-title":"Aesthetic Plast Surg","doi-asserted-by":"crossref"},{"DOI":"10.1080/02844310500430003","key":"10.1016/j.jaad.2023.12.017_bib241","year":"2006","issue":null,"author":"Muneuchi","volume":"40","first-page":"111","unstructured":null,"article-title":"Long-term outcome of intralesional injection of triamcinolone acetonide for the treatment of keloid scars in Asian patients","journal-title":"Scand J Plast ReConstr Surg Hand Surg","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaad.2016.06.049","key":"10.1016/j.jaad.2023.12.017_bib242","year":"2016","issue":null,"author":"Riis","volume":"75","first-page":"1151","unstructured":null,"article-title":"Intralesional triamcinolone for flares of hidradenitis suppurativa (HS): a case series","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib243","year":"1962","issue":null,"author":"Seif-El-Nasr","volume":"45","first-page":"105","unstructured":null,"article-title":"Granuloma annulare. Report of a case treated successfully by intralesional triamcinolone injection","journal-title":"J Egypt Med Assoc","doi-asserted-by":null},{"DOI":"10.1111/j.1365-2133.1975.tb06481.x","key":"10.1016/j.jaad.2023.12.017_bib244","year":"1975","issue":null,"author":"Sparrow","volume":"93","first-page":"85","unstructured":null,"article-title":"Granuloma annulare and necrobiosis lipoidica treated by jet injector","journal-title":"Br J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1111/jdv.15233","key":"10.1016/j.jaad.2023.12.017_bib245","year":"2019","issue":null,"author":"Zouboulis","volume":"33","first-page":"19","unstructured":null,"article-title":"Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization - systematic review and recommendations from the HS ALLIANCE working group","journal-title":"J Eur Acad Dermatol Venereol","doi-asserted-by":"crossref"},{"DOI":"10.2340/00015555-1346","key":"10.1016/j.jaad.2023.12.017_bib246","year":"2012","issue":null,"author":"Kwon","volume":"92","first-page":"241","unstructured":null,"article-title":"Clinical and histological effect of a low glycaemic load diet in treatment of acne vulgaris in Korean patients: a randomized, controlled trial","journal-title":"Acta Derm Venereol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib247","year":"2020","issue":null,"author":"Gallagher","volume":"13","first-page":"41","unstructured":null,"article-title":"Dermatologist use of intralesional triamcinolone in the treatment of acne","journal-title":"J Clin Aesthet Dermatol","doi-asserted-by":null},{"DOI":"10.1046/j.1365-4362.1998.00443.x","key":"10.1016/j.jaad.2023.12.017_bib248","year":"1998","issue":null,"author":"Jansen","volume":"37","first-page":"254","unstructured":null,"article-title":"Acne fulminans","journal-title":"Int J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/0190-9622(93)70076-6","key":"10.1016/j.jaad.2023.12.017_bib249","year":"1993","issue":null,"author":"Karvonen","volume":"28","first-page":"572","unstructured":null,"article-title":"Acne fulminans: report of clinical findings and treatment of twenty-four patients","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1080/14740338.2022.2102605","key":"10.1016/j.jaad.2023.12.017_bib250","year":"2022","issue":null,"author":"Villani","volume":"21","first-page":"1027","unstructured":null,"article-title":"Oral isotretinoin for acne: a complete overview","journal-title":"Expert Opin Drug Saf","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0190-9622(82)70063-5","key":"10.1016/j.jaad.2023.12.017_bib251","year":"1982","issue":null,"author":"Peck","volume":"6","first-page":"735","unstructured":null,"article-title":"Isotretinoin versus placebo in the treatment of cystic acne. A randomized double-blind study","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0190-9622(80)80074-0","key":"10.1016/j.jaad.2023.12.017_bib252","year":"1980","issue":null,"author":"Farrell","volume":"3","first-page":"602","unstructured":null,"article-title":"The treatment of severe cystic acne with 13-cis-retinoic acid: evaluation of sebum production and the clinical response in a multiple-dose trial","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1111/j.1365-2133.1982.tb00410.x","key":"10.1016/j.jaad.2023.12.017_bib253","year":"1982","issue":null,"author":"King","volume":"107","first-page":"583","unstructured":null,"article-title":"A double-blind study of the effects of 13-cis-retinoic acid on acne, sebum excretion rate and microbial population","journal-title":"Br J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0190-9622(84)80100-0","key":"10.1016/j.jaad.2023.12.017_bib254","year":"1984","issue":null,"author":"Strauss","volume":"10","first-page":"490","unstructured":null,"article-title":"Isotretinoin therapy for acne: results of a multicenter dose-response study","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1111/jdv.12170","key":"10.1016/j.jaad.2023.12.017_bib255","year":"2014","issue":null,"author":"Rademaker","volume":"28","first-page":"747","unstructured":null,"article-title":"Isotretinoin 5 mg daily for low-grade adult acne vulgaris--a placebo-controlled, randomized double-blind study","journal-title":"J Eur Acad Dermatol Venereol","doi-asserted-by":"crossref"},{"DOI":"10.1503/cmaj.140665","key":"10.1016/j.jaad.2023.12.017_bib256","year":"2016","issue":null,"author":"Asai","volume":"188","first-page":"118","unstructured":null,"article-title":"Management of acne: Canadian clinical practice guideline","journal-title":"CMAJ","doi-asserted-by":"crossref"},{"DOI":"10.1111/jdv.13675","key":"10.1016/j.jaad.2023.12.017_bib257","year":"2016","issue":null,"author":"Gollnick","volume":"30","first-page":"1480","unstructured":null,"article-title":"A consensus-based practical and daily guide for the treatment of acne patients","journal-title":"J Eur Acad Dermatol Venereol","doi-asserted-by":"crossref"},{"DOI":"10.1111/bjd.15843","key":"10.1016/j.jaad.2023.12.017_bib258","year":"2017","issue":null,"author":"Le Cleach","volume":"177","first-page":"908","unstructured":null,"article-title":"Guidelines for the management of acne: recommendations from a French multidisciplinary group","journal-title":"Br J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaad.2017.09.078","key":"10.1016/j.jaad.2023.12.017_bib259","year":"2018","issue":null,"author":"Thiboutot","volume":"78","first-page":"S1","unstructured":null,"article-title":"Practical management of acne for clinicians: an international consensus from the global alliance to improve outcomes in acne","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib260","year":"2019","issue":null,"author":"Gómez-Flores","volume":"56","first-page":"441","unstructured":null,"article-title":"[Second joint position paper: use of isotretinoin in severe acne]","journal-title":"Rev Med Inst Mex Seguro Soc","doi-asserted-by":null},{"DOI":"10.1016/j.abd.2020.09.001","key":"10.1016/j.jaad.2023.12.017_bib261","year":"2020","issue":"Suppl 1","author":"Bagatin","volume":"95","first-page":"19","unstructured":null,"article-title":"Consensus on the use of oral isotretinoin in dermatology - Brazilian Society of Dermatology","journal-title":"An Bras Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1111/dth.15974","key":"10.1016/j.jaad.2023.12.017_bib262","year":"2022","issue":null,"author":"Kassem","volume":"35","first-page":null,"unstructured":null,"article-title":"Evaluation of the efficacy and relapse rates of treatment protocols for moderate acne using isotretinoin based on the global acne grading system: randomized, controlled, comparative study","journal-title":"Dermatol Ther","doi-asserted-by":"crossref"},{"DOI":"10.1111/j.1468-3083.2010.03933.x","key":"10.1016/j.jaad.2023.12.017_bib263","year":"2011","issue":null,"author":"Borghi","volume":"25","first-page":"1094","unstructured":null,"article-title":"Low-cumulative dose isotretinoin treatment in mild-to-moderate acne: efficacy in achieving stable remission","journal-title":"J Eur Acad Dermatol Venereol","doi-asserted-by":"crossref"},{"DOI":"10.1111/j.1468-3083.2006.01784.x","key":"10.1016/j.jaad.2023.12.017_bib264","year":"2006","issue":null,"author":"Kaymak","volume":"20","first-page":"1256","unstructured":null,"article-title":"The effectiveness of intermittent isotretinoin treatment in mild or moderate acne","journal-title":"J Eur Acad Dermatol Venereol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaad.2005.11.1061","key":"10.1016/j.jaad.2023.12.017_bib265","year":"2006","issue":null,"author":"Amichai","volume":"54","first-page":"644","unstructured":null,"article-title":"Low-dose isotretinoin in the treatment of acne vulgaris","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib266","year":"2014","issue":null,"author":"Kızılyel","volume":"94","first-page":"234","unstructured":null,"article-title":"Effects of oral isotretinoin on lipids and liver enzymes in acne patients","journal-title":"Cutis","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib267","year":"2006","issue":null,"author":"Ghaffarpour","volume":"5","first-page":"878","unstructured":null,"article-title":"Oral isotretinoin for acne, adjusting treatment according to patient's response","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":"10.1590/1516-3180.2018.054405072019","key":"10.1016/j.jaad.2023.12.017_bib268","year":"2019","issue":null,"author":"Evaristo","volume":"137","first-page":"363","unstructured":null,"article-title":"Use of oral isotretinoin to treat acne in the public system: a hospital-based retrospective cohort","journal-title":"Sao Paulo Med J","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaad.2019.06.025","key":"10.1016/j.jaad.2023.12.017_bib269","year":"2020","issue":null,"author":"Barbieri","volume":"82","first-page":"72","unstructured":null,"article-title":"The clinical utility of laboratory monitoring during isotretinoin therapy for acne and changes to monitoring practices over time","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1111/jocd.12268","key":"10.1016/j.jaad.2023.12.017_bib270","year":"2017","issue":null,"author":"Yap","volume":"16","first-page":"348","unstructured":null,"article-title":"Safety and efficacy of fixed-dose 10 mg daily isotretinoin treatment for acne vulgaris in Malaysia","journal-title":"J Cosmet Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1001/jamadermatol.2015.3091","key":"10.1016/j.jaad.2023.12.017_bib271","year":"2016","issue":null,"author":"Lee","volume":"152","first-page":"35","unstructured":null,"article-title":"Laboratory monitoring during isotretinoin therapy for acne: a systematic review and meta-analysis","journal-title":"JAMA Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1001/jamadermatol.2022.2044","key":"10.1016/j.jaad.2023.12.017_bib272","year":"2022","issue":null,"author":"Xia","volume":"158","first-page":"942","unstructured":null,"article-title":"Isotretinoin laboratory monitoring in acne treatment: a Delphi consensus study","journal-title":"JAMA Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1111/bjd.21840","key":"10.1016/j.jaad.2023.12.017_bib273","year":"2022","issue":null,"author":"Affleck","volume":"187","first-page":"857","unstructured":null,"article-title":"Is routine laboratory testing in healthy young patients taking isotretinoin necessary: a critically appraised topic","journal-title":"Br J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/0190-9622(92)70088-W","key":"10.1016/j.jaad.2023.12.017_bib274","year":"1992","issue":null,"author":"Dai","volume":"26","first-page":"599","unstructured":null,"article-title":"Epidemiology of isotretinoin exposure during pregnancy","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaad.2010.09.017","key":"10.1016/j.jaad.2023.12.017_bib275","year":"2011","issue":null,"author":"Shin","volume":"65","first-page":"1117","unstructured":null,"article-title":"The impact of the iPLEDGE program on isotretinoin fetal exposure in an integrated health care system","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaad.2013.08.034","key":"10.1016/j.jaad.2023.12.017_bib276","year":"2014","issue":null,"author":"Collins","volume":"70","first-page":"55","unstructured":null,"article-title":"Compliance with pregnancy prevention measures during isotretinoin therapy","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib277","year":"2017","issue":null,"author":null,"volume":"130","first-page":"e251","unstructured":null,"article-title":"Practice bulletin No. 186: long-acting reversible contraception: implants and intrauterine devices","journal-title":"Obstet Gynecol","doi-asserted-by":null},{"DOI":"10.1038/jid.2012.387","key":"10.1016/j.jaad.2023.12.017_bib278","year":"2013","issue":null,"author":"Alhusayen","volume":"133","first-page":"907","unstructured":null,"article-title":"Isotretinoin use and the risk of inflammatory bowel disease: a population-based cohort study","journal-title":"J Invest Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1038/ajg.2009.417","key":"10.1016/j.jaad.2023.12.017_bib279","year":"2009","issue":null,"author":"Bernstein","volume":"104","first-page":"2774","unstructured":null,"article-title":"Isotretinoin is not associated with inflammatory bowel disease: a population-based case-control study","journal-title":"Am J Gastroenterol","doi-asserted-by":"crossref"},{"DOI":"10.1038/ajg.2010.124","key":"10.1016/j.jaad.2023.12.017_bib280","year":"2010","issue":null,"author":"Crockett","volume":"105","first-page":"1986","unstructured":null,"article-title":"Isotretinoin use and the risk of inflammatory bowel disease: a case-control study","journal-title":"Am J Gastroenterol","doi-asserted-by":"crossref"},{"DOI":"10.1001/jamadermatol.2013.1344","key":"10.1016/j.jaad.2023.12.017_bib281","year":"2013","issue":null,"author":"Etminan","volume":"149","first-page":"216","unstructured":null,"article-title":"Isotretinoin and risk for inflammatory bowel disease: a nested case-control study and meta-analysis of published and unpublished data","journal-title":"JAMA Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1038/ajg.2014.8","key":"10.1016/j.jaad.2023.12.017_bib282","year":"2014","issue":null,"author":"Racine","volume":"109","first-page":"563","unstructured":null,"article-title":"Isotretinoin and risk of inflammatory bowel disease: a French nationwide study","journal-title":"Am J Gastroenterol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaad.2020.07.042","key":"10.1016/j.jaad.2023.12.017_bib283","year":"2021","issue":null,"author":"Wright","volume":"84","first-page":"41","unstructured":null,"article-title":"Risk of new-onset inflammatory bowel disease among patients with acne vulgaris exposed to isotretinoin","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1001/jamadermatol.2014.1540","key":"10.1016/j.jaad.2023.12.017_bib284","year":"2014","issue":null,"author":"Rashtak","volume":"150","first-page":"1322","unstructured":null,"article-title":"Isotretinoin exposure and risk of inflammatory bowel disease","journal-title":"JAMA Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.sder.2005.04.003","key":"10.1016/j.jaad.2023.12.017_bib285","year":"2005","issue":null,"author":"Marqueling","volume":"24","first-page":"92","unstructured":null,"article-title":"Depression and suicidal behavior in acne patients treated with isotretinoin: a systematic review","journal-title":"Semin Cutan Med Surg","doi-asserted-by":"crossref"},{"DOI":"10.1136/bmj.c5812","key":"10.1016/j.jaad.2023.12.017_bib286","year":"2010","issue":null,"author":"Sundstrom","volume":"341","first-page":null,"unstructured":null,"article-title":"Association of suicide attempts with acne and treatment with isotretinoin: retrospective Swedish cohort study","journal-title":"BMJ","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jad.2021.09.055","key":"10.1016/j.jaad.2023.12.017_bib287","year":"2022","issue":null,"author":"Chen","volume":"296","first-page":"277","unstructured":null,"article-title":"Risk of psychiatric disorders in patients taking isotretinoin: a nationwide, population-based, cohort study in Taiwan","journal-title":"J Affect Disord","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaad.2021.01.107","key":"10.1016/j.jaad.2023.12.017_bib288","year":"2021","issue":null,"author":"Ugonabo","volume":"85","first-page":"878","unstructured":null,"article-title":"Psychiatric disorders and suicidal behavior in patients with acne prescribed oral antibiotics versus isotretinoin: analysis of a large commercial insurance claims database","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1001/archderm.136.10.1231","key":"10.1016/j.jaad.2023.12.017_bib289","year":"2000","issue":null,"author":"Jick","volume":"136","first-page":"1231","unstructured":null,"article-title":"Isotretinoin use and risk of depression, psychotic symptoms, suicide, and attempted suicide","journal-title":"Arch Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1001/jama.2015.18392","key":"10.1016/j.jaad.2023.12.017_bib290","year":"2016","issue":null,"author":"Siu","volume":"315","first-page":"380","unstructured":null,"article-title":"Screening for depression in adults: US preventive services task force recommendation statement","journal-title":"JAMA","doi-asserted-by":"crossref"},{"DOI":"10.1001/jamadermatol.2020.2330","key":"10.1016/j.jaad.2023.12.017_bib291","year":"2020","issue":null,"author":"Secrest","volume":"156","first-page":"1098","unstructured":null,"article-title":"Quality of life assessed using Skindex-16 scores among patients with acne receiving isotretinoin treatment","journal-title":"JAMA Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1080/09546634.2019.1577545","key":"10.1016/j.jaad.2023.12.017_bib292","year":"2019","issue":null,"author":"Bray","volume":"30","first-page":"796","unstructured":null,"article-title":"Is there an association between isotretinoin therapy and adverse mood changes? A prospective study in a cohort of acne patients","journal-title":"J Dermatolog Treat","doi-asserted-by":"crossref"},{"DOI":"10.1111/bjd.21049","key":"10.1016/j.jaad.2023.12.017_bib293","year":"2022","issue":null,"author":"Paljarvi","volume":"187","first-page":"64","unstructured":null,"article-title":"Isotretinoin and adverse neuropsychiatric outcomes: retrospective cohort study using routine data","journal-title":"Br J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1001/jama.2022.16946","key":"10.1016/j.jaad.2023.12.017_bib294","year":"2022","issue":null,"author":"Mangione","volume":"328","first-page":"1534","unstructured":null,"article-title":"Screening for depression and suicide risk in children and adolescents: US preventive services task force recommendation statement","journal-title":"JAMA","doi-asserted-by":"crossref"},{"DOI":"10.1001/jama.2022.16936","key":"10.1016/j.jaad.2023.12.017_bib295","year":"2022","issue":null,"author":"Mangione","volume":"328","first-page":"1438","unstructured":null,"article-title":"Screening for anxiety in children and adolescents: US preventive services task force recommendation statement","journal-title":"JAMA","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaad.2016.02.1148","key":"10.1016/j.jaad.2023.12.017_bib296","year":"2016","issue":null,"author":"Schrom","volume":"75","first-page":"237","unstructured":null,"article-title":"Depression screening using health questionnaires in patients receiving oral isotretinoin for acne vulgaris","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1097/DSS.0000000000001166","key":"10.1016/j.jaad.2023.12.017_bib297","year":"2017","issue":null,"author":"Waldman","volume":"43","first-page":"1249","unstructured":null,"article-title":"ASDS guidelines task force: consensus recommendations regarding the safety of lasers, dermabrasion, chemical peels, Energy devices, and skin surgery during and after isotretinoin use","journal-title":"Dermatol Surg","doi-asserted-by":"crossref"},{"DOI":"10.1007/s10103-022-03645-6","key":"10.1016/j.jaad.2023.12.017_bib298","year":"2022","issue":null,"author":"Scopelliti","volume":"37","first-page":"3639","unstructured":null,"article-title":"A novel 1726-nm laser system for safe and effective treatment of acne vulgaris","journal-title":"Lasers Med Sci","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaad.2023.05.085","key":"10.1016/j.jaad.2023.12.017_bib299","year":"2023","issue":"4","author":"Alexiades","volume":"89","first-page":"703","unstructured":null,"article-title":"Novel 1726 nm laser demonstrates durable therapeutic outcomes and tolerability for moderate-to-severe acne across skin types","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.3390/nu2101060","key":"10.1016/j.jaad.2023.12.017_bib300","year":"2010","issue":null,"author":"Reynolds","volume":"2","first-page":"1060","unstructured":null,"article-title":"Effect of the glycemic index of carbohydrates on Acne vulgaris","journal-title":"Nutrients","doi-asserted-by":"crossref"},{"DOI":"10.1093/ajcn/86.1.107","key":"10.1016/j.jaad.2023.12.017_bib301","year":"2007","issue":null,"author":"Smith","volume":"86","first-page":"107","unstructured":null,"article-title":"A low-glycemic-load diet improves symptoms in acne vulgaris patients: a randomized controlled trial","journal-title":"Am J Clin Nutr","doi-asserted-by":"crossref"},{"DOI":"10.4103/ijdvl.IJDVL_109_17","key":"10.1016/j.jaad.2023.12.017_bib302","year":"2019","issue":null,"author":"Pavithra","volume":"85","first-page":"486","unstructured":null,"article-title":"A randomized controlled trial of topical benzoyl peroxide 2.5% gel with a low glycemic load diet versus topical benzoyl peroxide 2.5% gel with a normal diet in acne (grades 1-3)","journal-title":"Indian J Dermatol Venereol Leprol","doi-asserted-by":"crossref"},{"DOI":"10.12788/cutis.0067","key":"10.1016/j.jaad.2023.12.017_bib303","year":"2020","issue":null,"author":"Barbieri","volume":"106","first-page":"E4","unstructured":null,"article-title":"Active comparator trial designs used to promote development of innovative new medications","journal-title":"Cutis","doi-asserted-by":"crossref"},{"DOI":"10.1001/jamadermatol.2021.0356","key":"10.1016/j.jaad.2023.12.017_bib304","year":"2021","issue":null,"author":"Miller","volume":"157","first-page":"597","unstructured":null,"article-title":"Use of active comparator trials for topical medications in dermatology","journal-title":"JAMA Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaad.2017.06.004","key":"10.1016/j.jaad.2023.12.017_bib305","year":"2017","issue":null,"author":"Gao","volume":"77","first-page":"971","unstructured":null,"article-title":"Acne, sexual orientation, and mental health among young adults in the United States: a population-based, cross-sectional study","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib306","year":"2022","issue":null,"author":"Pathmarajah","volume":"15","first-page":"43","unstructured":null,"article-title":"Acne vulgaris in skin of color: a systematic review of the effectiveness and tolerability of current treatments","journal-title":"J Clin Aesthet Dermatol","doi-asserted-by":null},{"DOI":"10.1001/jamadermatol.2020.5353","key":"10.1016/j.jaad.2023.12.017_bib307","year":"2021","issue":null,"author":"Braun","volume":"157","first-page":"344","unstructured":null,"article-title":"Moderate-to-severe acne and mental health symptoms in Transmasculine persons who have received testosterone","journal-title":"JAMA Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jid.2020.05.086","key":"10.1016/j.jaad.2023.12.017_bib308","year":"2021","issue":null,"author":"DeGrazia","volume":"141","first-page":"189","unstructured":null,"article-title":"Eligibility criteria related to hormone therapy in acne clinical trials: a systematic review","journal-title":"J Invest Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2023.12.017_bib309","year":"2022","issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1016/j.jaad.2018.02.042","key":"10.1016/j.jaad.2023.12.017_bib310","year":"2019","issue":null,"author":"Yeung","volume":"80","first-page":"581","unstructured":null,"article-title":"Dermatologic care for lesbian, gay, bisexual, and transgender persons: terminology, demographics, health disparities, and approaches to care","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaad.2013.09.009","key":"10.1016/j.jaad.2023.12.017_bib311","year":"2014","issue":null,"author":"Butler","volume":"70","first-page":"417.e1","unstructured":null,"article-title":"Safety of dermatologic medications in pregnancy and lactation: part II. Lactation","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"}],"short-title":[],"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"update-policy":"https://doi.org/10.1016/elsevier_cm_policy","alternative-id":["S0190962223033893"],"content-domain":{"domain":["clinicalkey.fr","jaad.org","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"original-title":[],"container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2024,5]]},"reference-count":312,"published-online":null,"references-count":312,"short-container-title":["Journal of the American Academy of Dermatology"],"is-referenced-by-count":189},"unpaywall":{"doi":"10.1016/j.jaad.2023.12.017","is_oa":true,"title":"Guidelines of care for the management of acne vulgaris","updated":"2025-08-17T18:46:03+00:00","published_date":"2024-01-30","best_oa_location":{"url":"http://www.jaad.org/article/S0190962223033893/pdf","pmh_id":null,"url_for_pdf":"http://www.jaad.org/article/S0190962223033893/pdf","url_for_landing_page":"https://doi.org/10.1016/j.jaad.2023.12.017"}}},"created_at":"2025-09-20T08:37:26.392Z","updated_at":"2025-09-20T08:53:46.685Z","tags":[{"paper_doi":"10.1016/j.jaad.2023.12.017","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2023.12.017","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2023.12.017","tag_type":"condition","value":"Acne Vulgaris","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2023.12.017","tag_type":"generic","value":"azelaic acid","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2023.12.017","tag_type":"generic","value":"clascoterone","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2023.12.017","tag_type":"generic","value":"doxycycline","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2023.12.017","tag_type":"generic","value":"isotretinoin","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2023.12.017","tag_type":"generic","value":"minocycline","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2023.12.017","tag_type":"generic","value":"salicylic acid","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2023.12.017","tag_type":"generic","value":"sarecycline","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2023.12.017","tag_type":"generic","value":"spironolactone","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2023.12.017","tag_type":"modality","value":"Androgen Receptor Inhibitor","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2023.12.017","tag_type":"modality","value":"Hormonal Therapy","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2023.12.017","tag_type":"modality","value":"Intralesional Corticosteroid","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2023.12.017","tag_type":"modality","value":"Oral Retinoid","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2023.12.017","tag_type":"modality","value":"Oral Tetracycline","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2023.12.017","tag_type":"modality","value":"Topical Antibiotic","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2023.12.017","tag_type":"modality","value":"Topical Keratolytic","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2023.12.017","tag_type":"modality","value":"Topical Retinoid","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2023.12.017","tag_type":"study_design","value":"Clinical Practice Guideline","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2023.12.017","tag_type":"warning","value":"Design classification noted as a clinical practice guideline based on a systematic review with GRADE; taxonomy may vary across sources.","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2023.12.017","tag_type":"warning","value":"Only high-level recommendations are available in the provided text; quantitative outcomes and dosing details are not included here.","value_numeric":null}],"summaries":{"what_studied":"An evidence-based clinical guideline for acne vulgaris, developed via systematic review using GRADE, covering management in preadolescents (≥9 years), adolescents, and adults.","key_result":"The guideline issues 18 recommendations and 5 good practice statements: strong recommendations for benzoyl peroxide, topical retinoids, topical antibiotics, and oral doxycycline; strong for oral isotretinoin in severe, scarring/psychosocial burden, or refractory acne; conditional for topical clascoterone, salicylic acid, and azelaic acid, and for oral minocycline, sarecycline, combined oral contraceptives, and spironolactone; good practice to combine topical agents with different mechanisms, limit systemic antibiotic use, pair systemic antibiotics with topicals, and add intralesional corticosteroids for larger lesions.","practice_takeaway":"Use benzoyl peroxide and a topical retinoid (± topical antibiotic) as core therapy; add oral doxycycline when needed, and reserve isotretinoin for severe, scarring/psychosocial burden, or refractory cases. Consider clascoterone, salicylic or azelaic acid, minocycline or sarecycline, combined oral contraceptives, or spironolactone as conditionally recommended options; combine topicals, minimize systemic antibiotic exposure, and use intralesional corticosteroids for large lesions."}}],"initialOffset":15,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"generic","value":"doxycycline"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Generics","href":"/hub/tag/generic"},{"name":"doxycycline"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"generic","hub_tag_value":"doxycycline"}}}]]

Papers